Deposits and other long-term assets

5,529

^[1]

7,539

Deferred license fees

118

322

1,031

1,299

Equity method investment in Asterias, at fair value (Note 4)

100,039

Equity method investment in Ascendance

4,671

Accounts payable and accrued liabilities

10,206

^[2]

33,592

TOTAL ASSETS

142,572

94,660

CURRENT LIABILITIES

7,144

^[3]

9,377

Capital lease liability, current portion

202

Promissory notes, current portion

Related party convertible debt

833

Deferred grant income

2,513

Deferred license and subscription revenue, current portion

572

439

Total current liabilities

8,850

12,462

LONG-TERM LIABILITIES

Deferred revenues, net of current portion

308

615

Deferred rent liabilities, net of current portion

158

Lease liability

1,386

4,400

Capital lease liability, net of current portion

310

1,032

324

Promissory notes, net of current portion

120

220

Other long term liabilities

TOTAL LIABILITIES

12,064

18,213

Commitments and contingencies (Note 11)

SHAREHOLDERS' EQUITY

Series A convertible preferred stock, no par value, authorized 2,000 shares as of December 31, 2016 and 2015; none issued and outstanding as of December 31, 2016 and 2015, respectively

Common stock, no par value, authorized 150,000 shares; issued and outstanding shares; 103,396 shares issued and 102,776 outstanding as of December 31, 2016 and 94,894 issued and 90,421 outstanding as of December 31, 2015

317,878

273,979

Accumulated other comprehensive loss

(738)

(237)

Accumulated deficit

(196,321)

(229,893)

Treasury stock at cost: 620 and 4,473 shares at December 31, 2016 and 2015, respectively

(2,891)

(18,033)

BioTime, Inc. shareholders' equity

117,928

25,816

Noncontrolling interest

12,580

50,631

Total shareholders' equity

130,508

76,447

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

$ 142,572

$ 94,660

[1]	(1) Reflects the effect of the Asterias Deconsolidation.
[2]	Reflects the effect of the Deconsolidation.
[3]	Reflects the effect of the Asterias Deconsolidation.

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
SHAREHOLDERS' EQUITY
Series A convertible preferred stock, par value (in dollars per share)	$ 0	$ 0
Series A convertible preferred stock, authorized (in shares)	2,000,000	2,000,000
Series A convertible preferred stock, issued (in shares)	0	0
Series A convertible preferred stock outstanding (in shares)	0	0
Common shares, par value (in dollars per share)	$ 0	$ 0
Common shares, authorized (in shares)	150,000,000	150,000,000
Common shares, issued (in shares)	103,396,245	94,894,140
Common shares, outstanding (in shares)	102,776,539	90,421,554
Treasury stock (in shares)	619,706	4,472,586

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
REVENUES:
Grant income	$ 3,671	$ 4,502	$ 3,297
Royalties from product sales and license fees	544	719	398
Subscription and advertisement	972	1,357	1,173
Sale of research products and services	736	458	376
Total revenues	5,923	7,036	5,244
Cost of sales	(358)	(1,107)	(837)
Gross profit	5,565	5,929	4,407
OPERATING EXPENSES:
Research and development	(36,106)	(42,604)	(37,533)
General and administrative	(28,426)	(29,134)	(17,556)
Total operating expenses	(64,532)	(71,738)	(55,089)
Loss from operations	(58,967)	(65,809)	(50,682)
OTHER INCOME/(EXPENSES):
Interest expense, net	(747)	(340)	(89)
BioTime's share of losses and impairment in equity method investment in Ascendance	(4,671)	(35)	0
Gain on deconsolidation of Asterias (Note 3)	49,048	0	0
Gain on equity method investment in Asterias at fair value (Note 4)	34,361	0	0
Gain on investment	0	3,694	0
Other income/(expense), net	(403)	(160)	(384)
Total other income/(expense), net	77,588	3,159	(473)
INCOME (LOSS) BEFORE INCOME TAX BENEFIT	18,621	(62,650)	(51,155)
Deferred income tax benefit	0	4,516	7,376
NET INCOME (LOSS)	18,621	(58,134)	(43,779)
Net loss attributable to noncontrolling interest	14,951	11,143	7,367
NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC.	33,572	(46,991)	(36,412)
Preferred stock dividend	0	(415)	(87)
NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS	$ 33,572	$ (47,406)	$ (36,499)
NET INCOME (LOSS) PER COMMON SHARE:
BASIC (in dollars per share)	$ 0.35	$ (0.59)	$ (0.55)
DILUTED (in dollars per share)	$ 0.34	$ (0.59)	$ (0.55)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING:
BASIC (in shares)	97,316	79,711	66,467
DILUTED (in shares)	99,553	79,711	66,467

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract]
NET INCOME (LOSS)	$ 18,621	$ (58,134)	$ (43,779)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment, net of tax	(106)	(424)	125
Available for sale investments:
Unrealized (loss)/gain on available for sale securities, net of taxes	(395)	1	(1)
COMPREHENSIVE INCOME (LOSS)	18,120	(58,557)	(43,655)
Less: comprehensive loss attributable to noncontrolling interest	14,951	11,143	7,367
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS BEFORE PREFERRED STOCK DIVIDEND	33,071	(47,414)	(36,288)
Preferred stock dividend	0	(415)	(87)
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS	$ 33,071	$ (47,829)	$ (36,375)

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Preferred Shares [Member]	Preferred Shares [Member] Asterias Biotherapeutics [Member]	Preferred Shares [Member] OncoCyte [Member]	Common Shares [Member]	Common Shares [Member] Asterias Biotherapeutics [Member]	Common Shares [Member] OncoCyte [Member]	Treasury Shares [Member]	Treasury Shares [Member] Asterias Biotherapeutics [Member]	Treasury Shares [Member] OncoCyte [Member]	Contributed Capital [Member]	Contributed Capital [Member] Asterias Biotherapeutics [Member]	Contributed Capital [Member] OncoCyte [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member] Asterias Biotherapeutics [Member]	Accumulated Deficit [Member] OncoCyte [Member]	Non-controlling Interest [Member]	Non-controlling Interest [Member] Asterias Biotherapeutics [Member]	Non-controlling Interest [Member] OncoCyte [Member]	Accumulated Other Comprehensive Income/(Loss) [Member]	Accumulated Other Comprehensive Income/(Loss) [Member] Asterias Biotherapeutics [Member]	Accumulated Other Comprehensive Income/(Loss) [Member] OncoCyte [Member]	Total	Asterias Biotherapeutics [Member]	OncoCyte [Member]
BALANCE at Dec. 31, 2013	$ 0			$ 203,456			$ (43,034)			$ 94			$ (145,778)			$ 27,461			$ 62			$ 42,261
BALANCE (in shares) at Dec. 31, 2013	0			67,412,000			(10,698,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of common shares, net of fees paid and amortized	$ 0			$ 43,827			$ 0			0			0			0			0			43,827
Sale of common shares, net of fees paid and amortized (in shares)	0			14,173,000			0
Exercise of options	$ 0			$ 1,192			$ 0			0			0			0			0			1,192
Exercise of options (in shares)	0			2,060,000			0
Shares retired as part of exercise of options	$ 0			$ (973)			$ 0			0			0			0			0			(973)
Shares retired as part of exercise of options (in shares)	0			(367,000)			0
Shares retired to pay for employee's taxes	$ 0			$ (415)			$ 0			0			0			0			0			(415)
Shares retired to pay for employee's taxes (in shares)	0			(156,000)			0
Tax liability on treasury shares sold by Asterias	$ 0			$ (3,611)			$ 0			0			0			0			0			(3,611)
Stock options granted for compensation	0			2,409			0			0			0			0			0			2,409
Stock options granted for compensation in subsidiaries	0			0			0			0			0			1,808			0			1,808
Restricted stock granted for compensation	0			0			0			0			0			234			0			234
Subsidiary warrants issued to outside investors as part of sale of treasury stock	0			0			0			0			0			3,184			0			3,184
Sale of treasury stock	$ 0			$ (11,042)			$ 23,144			0			0			0			0			12,102
Sale of treasury stock (in shares)	0			0			5,804,000
Sale of preferred stock	$ 3,500			$ 0			$ 0			0			0			0			0			3,500
Sale of preferred stock (in shares)	70,000			0			0
Dividends on preferred stock	$ 0			$ 0			$ 0			(87)			0			0			0			(87)
Outside investment in subsidiary with cash	0			0			0			0			0			939			0			939
Exercise of subsidiary options	0			0			0			0			0			8			0			8
Foreign currency translation adjustment	0			0			0			0			0			0			125			125
Unrealized loss on available-for-sale securities	0			0			0			0			0			0			(1)			(1)
NET INCOME (LOSS)	0			0			0			0			(36,412)			(7,367)			0			(43,779)
BALANCE at Dec. 31, 2014	$ 3,500			$ 234,843			$ (19,890)			7			(182,190)			26,267			186			62,723
BALANCE (in shares) at Dec. 31, 2014	70,000			83,122,000			(4,894,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of common shares, net of fees paid and amortized	$ 0			$ 33,897			$ 0			0			0			0			0			33,897
Sale of common shares, net of fees paid and amortized (in shares)	0			10,738,000			0
Exercise of options	$ 0			$ 621			$ 0			0			0			0			0			621
Exercise of options (in shares)	0			155,000			0
Shares retired as part of exercise of options																						0
Warrants exercised	$ 0			$ 19			$ 0			0			0			0			0			19
Warrants exercised (in shares)	0			4,000			0
Stock options granted for compensation	$ 0			$ 2,003			$ 0			0			0			0			0			2,003
Stock options granted for compensation in subsidiaries	0			0			0			0			0			8,223			0			8,223
Restricted stock granted for compensation	0			0			0			0			0			822			0			822
Dividend in kind	0			0			0			0			(712)			712			0			0
Subsidiary shares retired to pay for employee's taxes	0			0			0			0			0			(98)			0			(98)
Subsidiary warrants exercised	0			0			0			0			0			11,700			0			11,700
Contingently issuable subsidiary warrants	0			0			0			0			0			65			0			65
Sale of treasury stock	$ 0			$ (496)			$ 1,857			0			0			0			0			1,361
Sale of treasury stock (in shares)	0			0			421,000
Conversion of preferred stock to common stock	$ (3,500)			$ 3,500			$ 0			0			0			0			0			0
Conversion of preferred stock to common stock (in shares)	(70,000)			875,000			0
Dividends on preferred stock	$ 0			$ (408)			$ 0			(7)			0			0			0			(415)
Subsidiary shares issued in lieu of cash for services received	0			0			0			0			0			486			0			486
Outside investment in subsidiary with cash	0			0			0			0			0			3,918			0			3,918
Sale of subsidiary shares at- the- market, net of fees paid and amortized	0			0			0			0			0			9,646			0			9,646
Exercise of subsidiary options	0			0			0			0			0			33			0			33
Foreign currency translation adjustment	0			0			0			0			0			0			(424)			(424)
Unrealized loss on available-for-sale securities	0			0			0			0			0			0			1			1
NET INCOME (LOSS)	0			0			0			0			(46,991)			(11,143)			0			(58,134)
BALANCE at Dec. 31, 2015	$ 0			$ 273,979			$ (18,033)			0			(229,893)			50,631			(237)			$ 76,447
BALANCE (in shares) at Dec. 31, 2015	0			94,894,000			(4,473,000)															90,421,554
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of common shares, net of fees paid and amortized	$ 0			$ 18,606			$ 0			0			0			0			0			$ 18,606
Sale of common shares, net of fees paid and amortized (in shares)	0			8,420,000			0
Common shares issued for executive bonus in lieu of cash	$ 0			$ 200			$ 0			0			0			0			0			200
Common shares issued for executive bonus in lieu of cash (in shares)	0			68,000			0
Common shares issued for consulting services in lieu of cash	$ 0			$ 40			$ 0			0			0			0			0			40
Common shares issued for consulting services in lieu of cash (in shares)	0			14,000			0
Stock options granted for compensation	$ 0			$ 2,731			$ 0			0			0			0			0			2,731
Stock options granted for compensation in subsidiaries	0			0			0			0			0			5,220			0			5,220
Dividends on preferred stock																						0
Deconsolidation of Asterias	$ 0			$ 0			$ 15,142			0			0			(21,752)			0			(6,610)
Deconsolidation of Asterias (in shares)	0			0			3,853,000
Subsidiary financing transactions with noncontrolling interests		$ 0	$ 0		$ 18,310	$ 4,012		$ 0	$ 0		$ 0	$ 0		$ 0	$ 0		$ (18,310)	$ (4,012)		$ 0	$ 0		$ 0	$ 0
Distribution of Asterias warrants to its shareholders other than BioTime	$ 0			$ 0			$ 0			0			0			3,125			0			3,125
Exercise of subsidiary options	0			0			0			0			0			2,151			0			2,151
Sale of common shares and warrants by OncoCyte, net of financing fees	0			0			0			0			0			9,777			0			9,777
Beneficial conversion feature on convertible debt issued to Cell Cure's noncontrolling interests	0			0			0			0			0			701			0			701
Foreign currency translation adjustment	0			0			0			0			0			0			(106)			(106)
Unrealized loss on available-for-sale securities	0			0			0			0			0			0			(395)			(395)
NET INCOME (LOSS)	0			0			0			0			33,572			(14,951)			0			18,621
BALANCE at Dec. 31, 2016	$ 0			$ 317,878			$ (2,891)			$ 0			$ (196,321)			$ 12,580			$ (738)			$ 130,508
BALANCE (in shares) at Dec. 31, 2016	0			103,396,000			(620,000)															102,776,539	21,700,000

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) attributable to BioTime, Inc.	$ 33,572	$ (46,991)	$ (36,412)
Net loss allocable to non-controlling interest	(14,951)	(11,143)	(7,367)
Adjustments to reconcile net income (loss) attributable to BioTime, Inc. to net cash used in operating activities:
Gain on deconsolidation of Asterias (Note 3)	(49,048)	0	0
Unrealized gain on equity method investment in Asterias at fair value	(34,361)	0	0
BioTime's share of losses and impairment of Ascendance	4,671	35	0
Gain on sale of assets	0	(3,694)	0
Depreciation expense, including amortization of leasehold improvements	1,180	1,078	1,051
Amortization of intangible assets	3,577	5,256	7,360
Amortization of deferred grant income	1,496	0	0
Amortization of deferred consulting fees	0	0	19
Amortization of deferred license fees	113	114	110
Amortization of deferred license, royalty and subscription revenues	(308)	102	(1)
Amortization of prepaid rent in common stock	0	63	85
Stock-based compensation	7,951	11,050	4,455
Subsidiary shareholder expense for subsidiary warrants	3,125	0	0
Subsidiary common stock issued in lieu of cash for services	0	486	0
Amortization of discount on related party convertible debt	448	245	56
Bad debt expense	950	0	(16)
Deferred income tax benefit	0	(4,516)	(7,376)
Other	0	66	9
Changes in operating assets and liabilities:
Accounts receivable, net	(39)	(248)	(74)
Grant receivable	226	168	11
Inventory	0	(75)	(87)
Prepaid expenses and other current assets	(1,115)	(1,458)	(86)
Other long-term assets	0	(100)	0
Accounts payable and accrued liabilities	12	1,673	(470)
Accrued interest on related party convertible debt	0	19	4
Other long-term liabilities	(56)	(20)	(160)
Deferred grant income	0	2,513	0
Deferred rent liabilities	99	61	61
Deferred revenues	132	772	(26)
Net cash used in operating activities	(42,326)	(44,544)	(38,854)
CASH FLOWS FROM INVESTING ACTIVITIES:
Deconsolidation of cash and cash equivalents of Asterias	(8,376)	0	0
Purchase of property and equipment	(2,248)	(1,241)	(483)
Payments on construction in progress	(278)	(4,093)	(219)
Purchase of foreign available-for-sale securities	0	(748)	0
Payment for Ascendance equity method investment	0	(500)	0
Proceeds from the sale of equipment	0	0	9
Security deposit paid, net	13	(859)	(315)
Net cash used in investing activities	(10,889)	(7,441)	(1,008)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercises of stock options	0	621	219
Proceeds from sale of preferred stock	0	0	3,500
Proceeds from issuance of common shares	20,125	34,123	44,150
Fees paid on sale of common shares	(1,515)	0	(323)
Proceeds from exercise of warrants	0	20	0
Proceeds from exercise of subsidiary stock options	2,151	33	8
Proceeds from sale of treasury shares	0	1,347	0
Proceeds from exercise of subsidiary warrants	0	11,700	0
Proceeds from sale of treasury shares and issuance of subsidiary warrants	0	0	15,156
Proceeds from sale of subsidiary common shares	171	13,639	468
Fees paid on sale of subsidiary common shares	(106)	(693)	0
Reimbursement from landlord on construction in progress	567	3,789	0
Proceeds from issuance of related party convertible debt	1,757	255	471
Proceeds for the sale of common shares and warrants of subsidiary	10,550	0	0
Fees paid on sale of common shares and warrants of subsidiary	(773)	0	0
Repayment of capital lease obligation	(145)	(59)	(26)
Net cash provided by financing activities	32,782	64,775	63,623
Effect of exchange rate changes on cash and cash equivalents	292	(48)	230
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(20,141)	12,742	23,991
CASH AND CASH EQUIVALENTS:
At beginning of year	42,229	29,487	5,496
At end of year	22,088	42,229	29,487
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during year for interest	94	119	91
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES :
Employee options exercised with common stock		0	973
Capital expenditure funded by capital lease borrowing	626	34	115
Construction in progress in accounts payable and accrued expenses		524	186
Landlord receivable		(567)	(378)
Lease liability	1,385	4,400	378
Conversion of preferred stock to common stock	0	3,500	0
Promissory notes in exchange of preferred share dividends	0	363	0
Common stock issued in lieu of cash for bonus and services	240	0	0
Equity method investment in Ascendance in exchange for assets	$ 0	$ 4,706	$ 0

Organization, Basis of Presentation and Liquidity

12 Months Ended

Dec. 31, 2016

Organization, Basis of Presentation and Liquidity [Abstract]

Organization, Basis of Presentation and Liquidity

1. Organization, Basis of Presentation and Liquidity

General – BioTime is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. BioTime’s clinical programs are based on two platform technologies. The foundation of BioTime’s core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. The foundation of BioTime’s cell delivery platform is its HyStem^® 3-D cell and drug delivery matrix technology. BioTime’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery.

BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. ("AST") and OncoCyte Corporation ("OCX"), which BioTime founded and, until recently, were majority-owned and consolidated subsidiaries. Asterias (NYSE MKT: AST) is presently focused on advancing three clinical-stage programs that have the potential to address areas of high unmet medical need in the fields of neurology (spinal cord injury) and oncology (acute myeloid leukemia and lung cancer). OncoCyte (NYSE MKT: OCX) is developing confirmatory diagnostic tests for lung cancer, breast cancer, and bladder cancer utilizing novel liquid biopsy technology.

BioTime is also enabling early-stage programs in other new technologies through its own research programs as well as through other subsidiaries or affiliates.

As further discussed in Notes 3 and 4, effective May 13, 2016, BioTime deconsolidated Asterias financial statements and results of operations due to the decrease in BioTime’s percentage ownership in Asterias from 57.1% to 48.7% as a result of Asterias’ public offering of its common stock to raise capital for its operations (the “Asterias Deconsolidation”). Since May 13, 2016, BioTime has accounted for the Asterias common stock it holds using the equity method of accounting at fair value.

As further discussed in Note 16, on February 17, 2017, BioTime’s ownership of OncoCyte declined below 50% and BioTime deconsolidated the financial statements of OncoCyte from its consolidated financial statements. Beginning on February 17, 2017, BioTime will account for OncoCyte using the equity method of accounting at fair value.

Use of estimates - The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, valuing investments in nonconsolidated investees using the equity method, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards, debt or other equity instruments. Actual results could differ materially from those estimates.

Principles of consolidation – BioTime’s consolidated financial statements include the accounts of its subsidiaries. The following table reflects BioTime’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its operating subsidiaries as of December 31, 2016.

Subsidiary	Field of Business	BioTime Ownership	Country
Cell Cure Neurosciences Ltd.	Products to treat age-related macular degeneration	62.5%(1)	Israel
ES Cell International Pte. Ltd.	Stem cell products for research, including clinical grade cell lines produced under cGMP	100%	Singapore
LifeMap Sciences, Inc.	Biomedical, gene, disease, and stem cell databases and tools	77.9%	USA
LifeMap Sciences, Ltd.	Biomedical, gene, disease, and stem cell databases and tools	(2)	Israel
LifeMap Solutions, Inc.	Mobile health software	(2)	USA
OncoCyte Corporation (3)	Cancer diagnostics	51.1%	USA
OrthoCyte Corporation	Developing bone grafting products for orthopedic diseases and injuries	100%	USA
ReCyte Therapeutics, Inc.	Research and development involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders, ischemic conditions and brown adipocytes for type-2 diabetes and obesity	94.8%	USA

(1)

Includes shares owned by BioTime and ES Cell International Pte. Ltd.

(2)

LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.

(3)

See Note 16. Beginning February 17, 2017, BioTime deconsolidated OncoCyte and OncoCyte is no longer a subsidiary of BioTime as of that date.

All material intercompany accounts and transactions have been eliminated in consolidation. As of December 31, 2016, BioTime consolidated ReCyte Therapeutics, Inc. (“ReCyte”), OncoCyte, OrthoCyte Corporation (“OrthoCyte”), ES Cell International Pte. Ltd. (“ESI”), Cell Cure Neurosciences Ltd (“Cell Cure”), BioTime Asia, Limited (“BioTime Asia”), LifeMap Sciences, Inc. (“LifeMap Sciences”), LifeMap Sciences, Ltd., and LifeMap Solutions, Inc. (“LifeMap Solutions”) as BioTime has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of shareholders’ equity on BioTime’s consolidated balance sheets.

Liquidity – Since inception, BioTime has incurred significant operating losses and has funded its operations primarily through the issuance of equity securities, payments from research grants, royalties from product sales and sales of research products and services. At December 31, 2016, BioTime had an accumulated deficit of approximately $196 million, working capital of $17 million and shareholders’ equity of $131 million. BioTime has evaluated its projected cash flows and believes that its cash, cash equivalents, and available for sale securities of $12.5 million (not including cash held by OncoCyte) as of December 31, 2016, and the net proceeds of $18.7 million raised in the underwritten public offering on February 15, 2017 (see Note 16), provide sufficient cash, cash equivalents, and working capital to carry out BioTime’s current operations through at least twelve months from the issuance date of the consolidated financial statements included herein.

BioTime’s projected cash flows are subject to various risks and uncertainties. For example, clinical trials being conducted by Cell Cure will be funded in part with funds from grants and not from cash on hand. If Cell Cure were to lose its grant funding or BioTime is unable to continue to provide working capital to Cell Cure, or both, it may be required to delay, postpone, or cancel its clinical trials or limit the number of clinical trial sites, or otherwise reduce or curtail its operations unless it is able to obtain adequate financing from another source that could be used for its clinical trial. The unavailability or inadequacy of financing to meet future capital needs could force BioTime to modify, curtail, delay, or suspend some or all aspects of its planned operations. BioTime’s determination as to when it will seek new financing and the amount of financing that it will need will be based on BioTime’s evaluation of the progress its makes in its research and development programs, any changes to the scope and focus of those programs, and projection of future costs, revenues, and rates of expenditure. BioTime cannot assure that adequate financing will be available on favorable terms, if at all. Sales of additional equity securities by BioTime or its subsidiaries could result in the dilution of the interests of present shareholders.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2016

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Going concern assessment – With the implementation of FASB’s new standard on going concern, ASU No. 2014-15, beginning with the year ended December 31, 2016 and all annual and interim periods thereafter, BioTime will assess going concern uncertainty for its consolidated financial statements to determine if BioTime has sufficient cash and cash equivalents on hand and working capital to operate for a period of at least one year from the date the consolidated financial statements are issued or are available to be issued, which is referred to as the “look-forward period” as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to BioTime, BioTime will consider various scenarios, forecasts, projections, and estimates, and BioTime will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail those expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, BioTime makes certain assumptions concerning its ability to curtail or delay research and development programs and expenditures within the look-forward period in accordance with ASU No. 2014-15.

Revenue recognition – BioTime complies with Accounting Standards Codification, ASC 605-10 and recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Grant income is recognized when the related research and development expenses are incurred. Revenues from the sale of research products and services are primarily derived from the sale of hydrogels and stem cell products and are recognized when earned. Royalty revenues consist of product royalty payments. Royalties earned on product sales are recognized as revenue in the quarter in which the royalty reports are received from the licensee, rather than the quarter in which the sales took place. License fee revenues consist primarily of subscription and advertising revenue from LifeMap Sciences’ online databases and are recognized based upon applicable subscription or advertising periods. When BioTime or a subsidiary is entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime or its subsidiary has no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured. When BioTime or a subsidiary receives up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime or its subsidiary does have continuing performance obligations, the fees are deferred and amortized ratably over the performance period. If the performance period cannot be reasonably estimated, BioTime amortizes nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated. Milestone payments, if any, related to scientific or technical achievements, subject to substantial uncertainty, are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured.

Cash and cash equivalents – BioTime considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2016 and 2015, BioTime had $16.8 million and $35.5 million in money market funds, respectively, considered to be cash equivalents.

Restricted cash – BioTime has a certificate deposit in the amount of $847,000 included in deposits and other long-term assets as of December 31, 2016, as required under the Alameda Lease discussed in Note 11, as BioTime is restricted from using the cash for working capital purposes.

Trade accounts and grants receivable, net – Net trade receivables amounted to $344,000 and $754,000 and grants receivable amounted to $102,000 and $324,000 as of December 31, 2016 and 2015, respectively. Net trade receivables include allowance for doubtful accounts of approximately $543,000 as of December 31, 2016 for those amounts deemed uncollectible by BioTime. BioTime evaluates the collectability of its receivables based on a variety of factors, including the length of time receivables are past due and significant one-time events and historical experience. An additional reserve for individual accounts will be recorded if BioTime becomes aware of a customer’s inability to meet its financial obligations, such as in the case of bankruptcy filings or deterioration in the customer’s operating results or financial position. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted.

Concentrations of credit risk – Financial instruments that potentially subject BioTime to significant concentrations of credit risk consist primarily of cash and cash equivalents. BioTime limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, BioTime has not experienced any losses on such accounts.

Fair Value Measurements – Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value (ASC 820-10-50), Fair Value Measurements and Disclosures:

Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.

Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value.

In determining fair value, BioTime utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, BioTime has no financial assets or liabilities recorded at fair value on a recurring basis, except for cash and cash equivalents consisting of money market funds, shares BioTime holds in Asterias and the available-for-sale securities described below. These assets are measured at fair value using the applicable period-end quoted market prices as a Level 1 input.

The fair value of BioTime’s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying consolidated balance sheets. The carrying amounts of accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.

Equity method accounting for Asterias, at fair value – BioTime uses the equity method of accounting when it has the ability to exercise significant influence, but not control, as determined in accordance with GAAP, over the operating and financial policies of a company. For equity method investments, which BioTime has elected to measure at fair value, unrealized gains and losses are reported in the consolidated statements of operations as a non-operating gain or loss from equity method investments.

As further discussed in Note 4, effective May 13, 2016, BioTime owned approximately 49% of the outstanding common stock of Asterias and has elected to account for its Asterias shares at fair value using the equity method of accounting because since that date BioTime has not had control of Asterias, as defined by GAAP, but continues to exercise significant influence over Asterias. Under the fair value method, BioTime’s Asterias shares are marked to market using the closing price of Asterias common stock on the NYSE MKT multiplied by the number of shares of Asterias held by BioTime, with changes in the fair value of the Asterias shares included in other income/expenses, net, in the condensed consolidated statements of operations. The Asterias shares are considered a Level 1 asset as defined by ASC 820.

Available for sale securities in foreign investments – BioTime accounts for the shares it holds as available-for-sale foreign equity securities in accordance with ASC 320-10-25, Investments – Debt and Equity Securities, as the shares have a readily determinable fair value quoted on the Tel Aviv Stock Exchange, or TASE, (under trading symbol “HDST”). These securities are held principally as available for sale to meet future working capital needs and are denominated in New Israeli Shekels (NIS). The securities are measured at fair value and reported as current assets on the balance sheet based on the closing trading price of the security as of the date being presented. Unrealized holding gains and losses, including changes in foreign currency exchange rates, net of tax, are reported in other comprehensive income or loss. Realized gains and losses, and declines in value judged to be other-than-temporary related to equity securities, are included in other income or expenses, net, in the consolidated statements of operations.

Property, plant and equipment, net – Property, plant and equipment is stated at cost and is being depreciated using the straight-line method over their estimated useful lives ranging from 3 to 10 years. Leasehold improvements are amortized over the shorter of the useful life or the lease term.

Long-lived intangible assets – Long-lived intangible assets, consisting primarily of acquired patents, patent applications, and licenses to use certain patents are stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful lives of the assets, generally over 10 years.

Impairment of long-lived assets – Long-lived assets, including long-lived intangible assets, are reviewed annually for impairment and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If an impairment indicator is present, BioTime evaluates recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets. If the assets are impaired, the impairment recognized is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets.

Treasury stock – BioTime accounts for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet. BioTime has registered the BioTime common shares held by its subsidiaries for sale under the Securities Act of 1933, as amended (the “Securities Act”) to enhance the marketability of the shares.

Accounting for warrants – BioTime determines the accounting classification of warrants that it or its subsidiaries issue, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, and then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480-10, BioTime assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, in order to conclude equity classification, BioTime assesses whether the warrants are indexed to its common stock or its subsidiary’s common stock, as applicable, and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments are made, BioTime concludes whether the warrants are classified as liability or equity. Liability classified warrants are required to be accounted for at fair value both on the date of issuance and on subsequent accounting period ending dates, with all changes in fair value after the issuance date recorded in the consolidated statements of operations as a gain or loss. Equity classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized subsequent to the issuance date. BioTime does not have any liability classified warrants as of any period presented (see Note 9).

Investments in Common Stock of Privately Held Companies – BioTime evaluates whether investments held in common stock of an investee require consolidation of the entity under, first, the variable interest entity (“VIE”) model, and then under the Voting Interest model in accordance with accounting guidance for consolidations under Accounting Standards Codification (“ASC”) 810-10. If consolidation of the entity is not required under either the VIE model or the Voting Interest model, BioTime determines whether the equity method of accounting should be applied in accordance with ASC 323, Investments – Equity Method and Joint Ventures. The equity method applies to investments in common stock or in-substance common stock if BioTime exercises significant influence over, but does not control, the entity, typically represented by ownership of 20% or more of the voting interests of an entity.

BioTime initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment balance based on BioTime’s share of earnings or losses from the investment included in other income or expenses, net, on the consolidated statements of operations. The equity method investment balance is shown in noncurrent assets on the consolidated balance sheets.

BioTime reviews investments accounted for under the equity method for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be fully recoverable. If a determination is made that an “other-than-temporary” impairment exists, BioTime writes down its investment to fair value. Based on an evaluation and continuing losses and negative cash flows generated from the Ascendance investment, including uncertainty as to Ascendance’s ability to raise sufficient financing, BioTime determined that an other-than-temporary impairment existed on its equity method investment in Ascendance as of December 31, 2016, and BioTime wrote down the entire remaining $3.5 million carrying value of that investment included in other income and expenses, net.

Cost of sales – BioTime accounts for the cost of research products acquired for sale and any royalties paid as a result of any revenues in accordance with the terms of the applicable licensing agreements as cost of sales on the consolidated statement of operations.

Reclassifications – Certain immaterial reclassifications have been made to the year ended December 31, 2015 consolidated statements of changes in shareholders' equity to conform to the December 31, 2016 presentation. These reclassifications had no impact on the consolidated statements of operations, cash flows or consolidated shareholders' equity for any year presented.

Research and development – Research and development expenses consist of costs incurred for company-sponsored, collaborative and contracted research and development activities. These costs include direct and research-related overhead expenses including salaries, payroll taxes, consulting fees, research and laboratory fees, rent of research facilities, amortization of intangible assets, costs of patent applications, prosecution, and maintenance, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. BioTime expenses research and development costs as such costs are incurred. Research and development expenses incurred and reimbursed by grants from third parties approximate the grant income recognized in the consolidated statements of operations.

General and administrative – General and administrative expenses consist of compensation and related benefits, including stock-based compensation, for executive and corporate personnel; professional and consulting fees; and allocated overhead.

Foreign currency translation and other comprehensive loss, foreign currency transaction gains and losses – In countries in which BioTime operates, where the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the consolidated balance sheet date. Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the period. Resulting translation adjustments are recorded as a component of accumulated other comprehensive income or loss on the consolidated balance sheet. For the years ended December 31, 2016, 2015 and 2014, comprehensive income (loss) includes foreign currency translation adjustments, net of tax, of ($106,000), ($424,000) and $125,000, respectively.

For transactions denominated in other than the functional currency of BioTime, transactional gains and losses are recorded in other income and expense, net, included in the consolidated statements of operations. Foreign currency transaction gains and losses were not material for all periods presented.

Income taxes – BioTime accounts for income taxes in accordance with ASC 740, Income Taxes, which prescribe the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. ASC 740 guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. BioTime files a U.S. federal income tax return as well as various state and foreign income tax returns. BioTime’s judgments regarding future taxable income may change over time due to changes in market conditions, changes in tax laws, tax planning strategies or other factors. Certain majority-owned subsidiaries that BioTime consolidates under GAAP file their own, standalone federal income tax returns as those subsidiaries are not considered consolidated under federal income tax regulations, and accordingly, BioTime and those subsidiaries may not use each other’s tax attributes. If BioTime assumptions, and consequently the estimates, change in the future with respect to BioTime’s own deferred tax assets and liabilities, the valuation allowance may be increased or decreased, which may have a material impact on BioTime’s consolidated financial statements.

For California, Asterias’ activities were included in BioTime’s combined tax return through May 12, 2016. Beginning May 13, 2016, Asterias will file its own separate California income tax return (see Note 3) BioTime recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense, however, no amounts were accrued for the payment of interest and penalties as of December 31, 2016 and 2015. In general, BioTime is no longer subject to tax examination by major taxing authorities for years before 2012. Although the statute is closed for purposes of assessing additional income and tax in those years, the taxing authorities may still make adjustments to the net operating loss and credit carryforwards used in open years. Therefore, the statute should be considered open as it relates to the net operating loss and credit carryforwards. Any potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, state and local and foreign tax laws. Management does not expect that the total amount of unrecognized tax benefits will materially change over the next year.

As further discussed in Note 12, BioTime adopted early the provisions of Accounting Standards Update, ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, on a retrospective basis and due to the full valuation allowance on its deferred tax assets for all periods presented. The adoption did not have any impact on the consolidated financial statements.

Stock-based compensation – BioTime follows accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values less estimated forfeitures. Consistent with FASB guidelines, BioTime utilizes the Black-Scholes-Merton option pricing model for valuing share-based payment awards. BioTime’s determination of fair value of share-based payment awards on the date of grant using that option-pricing model is affected by BioTime’s stock price as well as by assumptions regarding a number of complex and subjective variables. These variables include, but are not limited to, BioTime’s expected stock price volatility over the term of the awards; the expected term of options granted, derived from historical data on employee exercises and post-vesting employment termination behavior; and a risk-free interest rate based on the U.S. Treasury rates in effect during the corresponding period of grant.

As further disclosed in Note 10, certain of BioTime’s privately-held consolidated subsidiaries have their own share-based compensation plans. For share-based compensation awards granted by those privately-held consolidated subsidiaries under their respective equity plans, BioTime determines the expected stock price volatility using historical prices of comparable public company common stock for a period equal to the expected term of the options. The expected term of privately-held subsidiary options is based upon the “simplified method” provided under Staff Accounting Bulletin, Topic 14, or SAB Topic 14. The fair value of the shares of common stock underlying the stock options of the privately-held consolidated subsidiaries is determined by the Board of Directors of those subsidiaries, as applicable, which is also used to determine the exercise prices of the stock options at the time of grant.

Although the fair value of employee stock options is determined in accordance with FASB guidance, changes in the assumptions can materially affect the estimated value and therefore the amount of compensation expense recognized in the consolidated financial statements.

Net income or loss per share – BioTime applies the two-class method for calculating basic earnings per share. Under the two-class method, net income, if any, will be reduced by preferred stock dividends and the residual amount is allocated between common stock and other participating securities based on their participation rights. Participating securities included only Series A convertible preferred stock, all of which was converted to common shares during 2015. Basic earnings per share is calculated by dividing net income or loss attributable to BioTime common shareholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock subject to repurchase by BioTime, if any, during the period. For periods in which BioTime reported a net loss, the participating securities were not contractually obligated to share in the losses of BioTime, and accordingly, no losses have been allocated to the participating securities during applicable periods. Diluted earnings per share is calculated by dividing the net income or loss attributable to BioTime common shareholders by the weighted average number of common shares outstanding, adjusted for the effects of potentially dilutive common stock, which are comprised of stock options and warrants, using the treasury-stock method, Series A convertible preferred stock, using the if-converted method, and shares of BioTime common stock held by subsidiaries.

The primary components of weighted average shares of potentially dilutive common shares used to compute diluted net income per common share for the year ended December 31, 2016, were approximately 2,030,000 BioTime common shares held by Asterias and OncoCyte (see Note 10), and approximately 206,000 restricted stock units and outstanding stock options. Outstanding warrants to purchase 9.4 million BioTime common shares were excluded from potentially dilutive common shares because the exercise price of the warrants exceeded the average closing price of BioTime common shares for the year ended December 31, 2016. For the years ended December 31, 2015 and 2014, because BioTime reported losses attributable to common stockholders, all potentially dilutive common stock is antidilutive for those periods. Diluted net loss per share for year ended December 31, 2015 excludes any effect from 4,472,586 treasury shares, 5,194,313 stock options and 10,109,860 common share purchase warrants outstanding, and for the year ended December 31, 2014 excludes 4,893,942 treasury shares, 3,974,326 stock options and 9,194,679 common share purchase warrants outstanding, because the inclusion would be antidilutive.

Recently Issued Accounting Pronouncements – The following accounting standards, which are not yet effective, are presently being evaluated by BioTime to determine the impact that they might have on its consolidated financial statements.

In December 2016, FASB issued Accounting Standards Update, ASU, 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers” (“ASU 2016-20”) which amends narrow aspects of accounting standard ASU 2014-09 “Revenue from Contracts with Customers (Topic 606).” ASU-2016-20 is effective for periods beginning after December 15, 2017.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”, which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgments and estimates may be required in the revenue recognition process than are required under existing GAAP. The revised revenue standard is effective for public entities for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures).

BioTime has completed an initial assessment of the new revenue recognition standard under Topic 606, which will be effective for BioTime beginning on January 1, 2018, and BioTime will be working on an implementation plan to evaluate the accounting and disclosure requirements under the new standard. Based on the work performed to date, BioTime does not expect adoption of the new standard to have a material impact on the consolidated financial statements. BioTime has not finalized its transition method for adoption.

In March 2016, the FASB issued ASU 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”, which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities, and classification of awards on the statement of cash flows. The update is effective for fiscal years beginning after December 15, 2016, and interim periods within those annual periods. BioTime is currently evaluating the impact the adoption of ASU 2016-09 will have on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which requires lessees to recognize assets and liabilities for leases with lease terms greater than twelve months in the statement of financial position. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. The update is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that reporting period. Early adoption is permitted. BioTime is currently evaluating the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.

Deconsolidation of Asterias	12 Months Ended
Deconsolidation of Asterias	Dec. 31, 2016
Deconsolidation of Asterias [Abstract]
Deconsolidation of Asterias	3. Deconsolidation of Asterias On May 13, 2016, Asterias completed the sale of 5,147,059 shares of its common stock and warrants to purchase 2,959,559 shares of its common stock, through an underwritten public offering (the “Asterias Offering”). Asterias received approximately $16.2 million in net proceeds from the Asterias Offering, after deduction of underwriting discounts, commissions and other expenses of the Asterias Offering. As a result of the sale of Asterias common stock in the Asterias Offering and the issuance of 708,333 shares of Asterias common stock upon the exercise of certain stock options by a former Asterias executive, as of May 13, 2016, BioTime’s percentage ownership of the outstanding common stock of Asterias declined to 48.7%. On May 13, 2016, BioTime experienced a loss of control of Asterias under GAAP (see Note 1). Accordingly, BioTime has deconsolidated Asterias financial statements and results of operations from BioTime (the “Asterias Deconsolidation”), effective May 13, 2016, in accordance with ASC, 810-10-40-4(c), Consolidation. Beginning on May 13, 2016, BioTime is accounting for the retained non-controlling interest in Asterias under the equity method of accounting and has elected the fair value option under ASC 825-10, Financial Instruments. In connection with the Asterias Deconsolidation and in accordance with ASC 810-10-40-5, BioTime recorded a gain on deconsolidation of $49.0 million during the year December 31, 2016 included in other income and expenses, net, in the consolidated statements of operations. BioTime held 21.7 million shares of Asterias common stock, or approximately 46% of Asterias outstanding common stock as of December 31, 2016.

Equity Method of Accounting for Common Stock of Asterias, at fair value

12 Months Ended

Dec. 31, 2016

Equity Method Accounting for Common Stock of Asterias, at fair value [Abstract]

Equity Method of Accounting for Common Stock of Asterias, at fair value

4. Equity Method of Accounting for Common Stock of Asterias, at fair value

BioTime elected to account for its 21.7 million shares of Asterias common stock at fair value using the equity method of accounting beginning on May 13, 2016, the date of the Asterias Deconsolidation. The Asterias shares had a fair value of $100.0 million as of December 31, 2016 and a fair value of $65.7 million as of May 13, 2016, based on the closing price of Asterias common stock on the NYSE MKT on those respective dates. For the year ended December 31, 2016, BioTime recorded unrealized gains of $34.3 million on the Asterias shares due to the increase in Asterias stock price from May 13, 2016 to December 31, 2016.

The condensed results of operations and condensed balance sheet information of Asterias are summarized below (in thousands):

	For the Year Ended December 31, 2016 ⁽¹⁾
Condensed Statements of Operations ⁽¹⁾:
Total revenue	$	6,954
Gross profit		6,826
Loss from operations		(34,123	)
Net loss	$	(35,038	)

	December 31, 2016		December 31, 2015
Condensed Balance Sheet information ⁽²⁾:
Current assets	$	36,990	$	29,789
Noncurrent assets		24,020		27,445
	$	61,010	$	57,234

Current liabilities	$	6,051	$	4,980
Noncurrent liabilities		12,930		7,155
Stockholders’ equity		42,029		45,099
	$	61,010	$	57,234

(1)

Asterias results of operations for the period from January 1, 2016 through May 12, 2016, the date immediately preceding the Asterias Deconsolidation, are included in the consolidated results of operations of BioTime for the year ended December 31, 2016 shown in the table below.

(2)

The condensed balance sheet information of Asterias as of December 31, 2016, provided for informational and comparative purposes only, was not included in BioTime’s consolidated balance sheet at December 31, 2016 due to the Asterias Deconsolidation on May 13, 2016. The condensed balance sheet information of Asterias as of December 31, 2015, included in the table above, was included in BioTime’s consolidated balance sheet at December 31, 2015, after intercompany eliminations.

The following table summarizes Asterias results of operations that are included in BioTime’s consolidated results of operations, after intercompany eliminations, for the period from January 1, 2016 through May 12, 2016, the date immediately preceding the Asterias Deconsolidation, and for the years ended December 31, 2015 and 2014 (in thousands).

	For the Period January 1, 2016 through May 12, 2016			Year Ended December 31, 2015			Year Ended December 31, 2014
Total revenue	$	2,354		$	3,582		$	1,224
Gross profit		2,301			3,314			1,129
Loss from operations		(13,944	)		(21,908	)		(17,461	)
Net loss	$	(13,113	)	$	(15,003	)	$	(10,097	)

Property, plant and equipment, net

12 Months Ended

Dec. 31, 2016

Property, plant and equipment, net [Abstract]

5. Property, plant and equipment, net

At December 31, 2016 and 2015, property, plant and equipment were comprised of the following (in thousands):

	December 31,
	2016(1)			2015
Equipment, furniture and fixtures	$	4,718		$	5,274
Leasehold improvements		3,791			5,623
Construction in progress		-			93
Accumulated depreciation and amortization		(2,980	)		(3,451	)
Property and equipment, net	$	5,529		$	7,539

(1)

Reflects the effect of the Asterias Deconsolidation.

Property, plant and equipment at December 31, 2016 include $626,000 and $33,800 financed by capital lease borrowings in 2016 and 2015, respectively. Depreciation and amortization expense amounted to $1.2 million, 1.1 million and $1.1 million for the years ended December 31, 2016, 2015 and 2014, respectively.

Leasehold improvements

Leasehold improvements of approximately $1.6 million was transferred to property, plant and equipment as of June 1, 2016 when BioTime completed construction of leasehold improvements at its new Alameda facility (see Note 5). Under the terms of the lease agreement, the landlord provided BioTime with an initial tenant improvement allowance of up to $1.4 million, which BioTime utilized entirely to construct a research and development laboratory, a diagnostic testing laboratory, and a small production facility that can be used to manufacture small cell banks and clinical materials for clinical studies. Additional leasehold improvements of approximately $200,000 paid by BioTime were not reimbursable by the landlord. The tenant improvements will be amortized over the shorter of the useful life of the assets or the lease term.

Intangible assets, net

12 Months Ended

Dec. 31, 2016

Intangible assets, net [Abstract]

6. Intangible assets, net

At December 31, 2016 and 2015, intangible assets, primarily consisting of acquired patents and accumulated amortization were as follows (in thousands):

	December 31,
	2016⁽¹⁾			2015
Intangible assets	$	25,703		$	52,563
Accumulated amortization		(15,497	)		(18,971	)
Intangible assets, net	$	10,206		$	33,592

(1)	Reflects the effect of the Asterias Deconsolidation.

BioTime amortizes its intangible assets over an estimated period of 10 years on a straight-line basis. BioTime recognized $3.6 million, $5.3 million and $7.4 million in amortization expense of intangible assets during the years ended December 31, 2016, 2015 and 2014, respectively.

Amortization of intangible assets for periods subsequent to December 31, 2016 is as follows (in thousands):

Year Ended December 31,	Amortization Expense
2017	$	2,570
2018		2,570
2019		2,571
2020		1,794
2021		537
Thereafter		164
Total	$	10,206

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	8. Related Party Transactions BioTime currently pays $5,050 per month for the use of approximately 900 square feet of office space in New York City, which is made available to BioTime on a month-by-month basis by one of its directors at an amount that approximates his cost. During the year ended December 31, 2016, Cell Cure issued certain convertible promissory notes (the “Convertible Debt”) to a Cell Cure shareholder other than BioTime in the principal amount of $1,757,000. In April and November 2015, Cell Cure issued Convertible Debt to a Cell Cure shareholder other than BioTime in the principal amount of $188,000 and $66,000, respectively. In July and September 2014, Cell Cure issued Convertible Debt to two Cell Cure shareholders other than BioTime in the principal amount of $471,000. One of the Cell Cure shareholders who acquired Convertible Debt is considered a related party. The functional currency of Cell Cure is the Israeli New Shekel however the Convertible Debt is payable in United States dollars. The Convertible Debt bears a stated interest rate of 3% per annum. The total outstanding principal balance of the Convertible Debt, with accrued interest, is due and payable on various maturity dates in July and September 2017, and in February and April 2019. The outstanding principal balance of the Convertible Debt with accrued interest is convertible into Cell Cure ordinary shares at a fixed conversion price of $20.00 per share, at the election of the holder, at any time prior to maturity. Any conversion of the Convertible Debt must be settled with Cell Cure ordinary shares and not with cash. The conversion feature of the Convertible Debt issued is not accounted for as an embedded derivative under the provisions of ASC 815, Derivatives and Hedging since it is not a freestanding financial instrument and the underlying Cell Cure ordinary shares are not readily convertible into cash. Accordingly, the Convertible Debt is accounted for under ASC 470-20, Debt with Conversion and Other Options (ASC 470-20). Under ASC 470-20, BioTime determined that a beneficial conversion feature (“BCF”) was present on the issuance dates of the Convertible Debt. A conversion feature is beneficial if, on the issuance dates, the effective conversion price is less than the fair value of the issuer’s capital stock. Since the effective conversion price of $20.00 per share is less than the estimated range of fair values from $28.00 per share to $40.00 per share of Cell Cure ordinary shares on the dates the Convertible Debt was issued, a beneficial conversion feature, equal to the intrinsic value ranging from $8 per share to $20 per share, is present. In accordance with ASC 470-20-30-8, if the intrinsic value of the BCF is greater than the proceeds allocated to the convertible instrument, the amount of the discount assigned to the BCF is limited to the amount of the proceeds allocated to the convertible instrument. The BCF is recorded as an addition to equity with a corresponding debt discount on the Convertible Debt issuance date. This debt discount will be amortized to interest expense using the effective interest method over the three-year term of the debt, representing an approximate effective annual interest rate between 11% and 23%. At December 31, 2016, the carrying value of the Convertible Debt was $1,865,000, comprised of principal and accrued interest of $2,544,000, net of unamortized debt discount of $679,000. As of December 31, 2015, the carrying value of the Convertible Debt was $324,000, comprised of principal and accrued interest of $748,000, net of unamortized debt discount of $424,000. At December 31, 2016, total accounts receivable from affiliates from shared services amounted to $511,000. In January 2016 and May 2016, certain BioTime board members invested in Ascendance as individual investors in Ascendance (see Note 2).

Shareholders' Equity

12 Months Ended

Dec. 31, 2016

Shareholders' Equity [Abstract]

Shareholders' Equity

9. Shareholders’ Equity

Preferred Shares

BioTime is authorized to issue 2,000,000 shares of preferred stock. The preferred shares may be issued in one or more series as the board of directors may by resolution determine. The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares. The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series. As of December 31, 2016, no shares of preferred stock were issued or outstanding.

Common Shares

BioTime is authorized to issue 150,000,000 common shares with no par value. As of December 31, 2016, BioTime had 103,396,245 issued and 102,776,539 outstanding common shares. As of December 31, 2015, BioTime had 94,894,140 issued and 90,421,554 outstanding common shares. The difference of 619,706 and 4,472,586 common shares as of December 31, 2016 and 2015, respectively, is attributed to shares held by BioTime subsidiaries which are accounted for as treasury stock on the consolidated balance sheet.

On June 16, 2016, BioTime sold 7,322,176 common shares in an underwritten public offering at a public offering price of $2.39 per share, for net proceeds of $16.4 million, after deducting underwriting discounts and commissions and other expenses. On July 5, 2016, BioTime issued an additional 1,098,326 common shares upon the full exercise of the over-allotment option by the underwriters for net proceeds of $2.2 million, after deducting underwriting discounts.

On February 15, 2017, BioTime sold 7,453,704, shares of common stock in an underwritten public offering (see Note 16).

Significant common share transactions during the year ended December 31, 2015 are as follows:

In September 2015, BioTime raised $8.6 million through the sale of 2,607,401 common shares at an offering price of $3.29 to three of its shareholders.

During October 2015, BioTime sold 6,530,612 common shares for $20.4 million in the aggregate to certain investment funds in Israel that hold shares of companies that are included within certain stock indexes of the TASE. The $3.13 purchase price per share was determined with reference to the closing price of BioTime common shares on the TASE on the date of sale. In addition, OncoCyte sold 246,356 BioTime common shares at the same price to one of the Israeli investment funds.

In October 2015, BioTime sold 1,600,000 common shares to a shareholder for $5.1 million. The $3.19 price of price per share was the closing price of the common shares on the NYSE MKT on October 1, 2015, the last trading day before BioTime and the shareholder entered into a purchase agreement for the sale of the shares.

On December 31, 2015, BioTime distributed 4.7 million shares of OncoCyte common stock to its shareholders, on a pro rata basis, accounted for as a dividend in kind. On this date, BioTime shareholders received one share of OncoCyte common stock for every twenty shares of BioTime common stock held. As a result of this distribution, BioTime recorded a reduction in the carrying value of its investment in OncoCyte with a corresponding increase to noncontrolling interests in OncoCyte in the amount of $712,000, representing the reduction in BioTime’s ownership in OncoCyte by 18.7% from 76.5% to 57.8%. BioTime continues to hold a controlling financial interest in OncoCyte. This distribution generated a taxable gain of approximately $7.4 million to BioTime, however BioTime had sufficient current year losses to offset the entire gain.

See Note 10 for a summary of all option activity under the stock option plans of all subsidiaries for the years ended December 31, 2016 and 2015.

Treasury Stock

Certain BioTime subsidiaries hold BioTime common shares that the subsidiaries received from BioTime in exchange for capital stock in the subsidiaries. The BioTime common shares held by subsidiaries are treated as treasury stock by BioTime and BioTime does not recognize a gain or loss on the sale of those shares by its subsidiaries.

As of December 31, 2016, all 619,706 shares of treasury stock were held by OncoCyte. Beginning on February 17, 2017, and in connection with the OncoCyte Deconsolidation, those treasury shares will be considered to be issued and outstanding BioTime common shares.

BioTime Warrants

BioTime has issued warrants to purchase its common shares. Activity related to warrants in 2016 and 2015 is presented in the table below (in thousands, except price per share):

	Number of Warrant Shares			Per Share Exercise Price		Weighted Average Exercise Price
Outstanding, January 1, 2014		9,752		$	5.00-10.00	$	5.29
Exercised in 2014		(557	)		10.00		10.00
Outstanding, December 31, 2014		9,195		$	5.00	$	5.00
Exercised in 2015		(4	)		5.00		5.00
Warrant adjustment⁽¹⁾		919
Outstanding, December 31, 2015		10,110		$	4.55	$	4.55
Expired in 2016		(715	)		4.55		4.55
Outstanding, December 31, 2016⁽²⁾		9,395		$	4.55	$	4.55

(1)

The number of shares issuable upon the exercise of the warrants was adjusted as a result of the distribution of OncoCyte common stock to BioTime shareholders during December 2015.

(2)

The 9,394,862 outstanding warrants will expire, if unexercised, beginning June 5, 2018 through September 30, 2018.

Issuance of common stock and warrants by OncoCyte

On August 29, 2016, OncoCyte sold an aggregate of 3,246,153 immediately separable units, with each unit consisting of one share of OncoCyte common stock and one warrant to purchase one share of OncoCyte common stock (the “OncoCyte Offering Warrants”), at a price of $3.25 per unit (the “OncoCyte Offering”) for net proceeds of $9.8 million, after deducting underwriting discounts, commissions and other expenses. The sales were made pursuant to the terms and conditions of certain Purchase Agreements between OncoCyte and the purchasers in the OncoCyte Offering. The purchasers included certain OncoCyte existing shareholders other than BioTime.

The OncoCyte Offering Warrants have an exercise price of $3.25 per OncoCyte share, and may be exercised for five years from October 17, 2016, the date the OncoCyte Warrants became exercisable.

The OncoCyte Offering Warrants may be exercised on a net “cashless exercise” basis, meaning that the value of a portion of the OncoCyte Offering Warrant shares may be used to pay the exercise price (rather than payment in cash), in certain circumstances, including if a resale registration statement is not effective under the Securities Act when and as required by the Purchase Agreements.

Under certain provisions of the OncoCyte Offering Warrants, in the event of a Fundamental Transaction, as defined in the OncoCyte Offering Warrants, OncoCyte will use reasonable best efforts for the acquirer, or any successor entity other than OncoCyte, to assume the OncoCyte Offering Warrants. If the acquirer does not assume the OncoCyte Offering Warrant obligations, then the acquirer shall pay the holders of OncoCyte Offering Warrants an amount equal to the aggregate value equal to the Black Scholes Value, as defined in the OncoCyte Offering Warrants. The payment of the Black Scholes Value shall be made in cash or such other consideration that the acquirer paid to the other OncoCyte shareholders in the Fundamental Transaction.

OncoCyte is not required to net cash settle the OncoCyte Offering Warrants under any circumstance. OncoCyte considered the guidance in ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. Since solely an acquirer of OncoCyte, and not OncoCyte itself, may be required to net cash settle the OncoCyte Offering Warrants in the event of a Fundamental Transaction, the OncoCyte Offering Warrants are classified as equity.

As more fully discussed in Note 16, on February 17, 2017, certain of OncoCyte investors exercised 625,000 OncoCyte Offering Warrants which caused BioTime’s ownership of the outstanding OncoCyte common stock to decline below 50%.

Transactions with Noncontrolling Interests of Asterias and OncoCyte

BioTime accounts for a change in ownership interests in its subsidiaries that does not result in a change of control of the subsidiary by BioTime under the provisions of ASC 810-10-45-23, Consolidation – Other Presentation Matters. This guidance is applicable when a noncontrolling shareholder invests in a subsidiary’s common stock resulting in a decrease in the ownership percentage held by the controlling shareholder in the subsidiary, but not below 50%, with the controlling shareholder retaining “control” of the subsidiary as defined by GAAP. In accordance with this guidance, a change in ownership interest that does not result in a change of control (of the subsidiary) is considered an “equity transaction”. When this occurs, although the total net assets of the subsidiary increase by the amount of the investment made by the noncontrolling shareholder, there is a proportional and immediate transfer of carrying value from the noncontrolling shareholder to the controlling shareholder immediately after the investment, based on the respective ownership percentages. The subsidiary financing transactions with noncontrolling interests in Asterias for $18.3 million, and OncoCyte for $4.0 million, reported in the consolidated statements of shareholders’ equity for the year ended December 31, 2016, represent this proportional transfer of carrying value to BioTime pertaining to investments in Asterias and OncoCyte common stock made by noncontrolling shareholders in which BioTime’s ownership was reduced, but not below 50%. (see Note 16).

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Stock Option Plans

12 Months Ended

Dec. 31, 2016

Stock Option Plans [Abstract]

Stock Option Plans

10. Stock Option Plans

During 2002, BioTime adopted the 2002 Employee Stock Option Plan (the “2002 Plan”), which was amended in 2004, 2007, and 2009 to reserve additional common shares for issuance under options or restricted stock awards granted to eligible persons. The 2002 Plan expired during September 2012 and no additional grants of options or awards of restricted stock may be made under the 2002 Plan.

During December 2012, BioTime’s Board of Directors approved the 2012 Equity Incentive Plan (the “2012 Plan”), which was amended during 2015, under which BioTime has reserved 10,000,000 common shares for the grant of stock options or the sale of restricted stock or other equity awards. No options may be granted under the 2012 Plan more than ten years after the date upon which the 2012 Plan was adopted by the Board of Directors, and no options granted under the 2012 Plan may be exercised after the expiration of ten years from the date of grant. Under the 2012 Plan, options to purchase common shares may be granted to employees, directors and certain consultants at prices not less than the fair market value at date of grant, subject to certain limited exceptions for options granted in substitution of other options. Options may be fully exercisable immediately, or may be exercisable according to a schedule or conditions specified by the Board of Directors or the Compensation Committee of the Board of Directors. The 2012 Plan also permits BioTime to award restricted stock for services rendered or to sell common shares to employees subject to vesting provisions under restricted stock agreements that provide for forfeiture of unvested shares upon the occurrence of specified events under a restricted stock award agreement. BioTime may permit employees or consultants, but not officers or directors, who purchase stock under restricted stock purchase agreements, to pay for their shares by delivering a promissory note that is secured by a pledge of their shares.

BioTime may also grant stock appreciation rights (“SARs”) and hypothetical units issued with reference to BioTime common shares (“Restricted Stock Units”) under the Plan. An SAR is the right to receive, upon exercise, an amount payable in cash or shares or a combination of cash and shares, as determined by the Board of Directors or the Compensation Committee, equal to the number of shares subject to the SAR that is being exercised multiplied by the excess of (a) the fair market value of a BioTime common share on the date the SAR is exercised, over (b) the exercise price specified in the SAR Award agreement.

The terms and conditions of a grant of Restricted Stock Units will be determined by the Board of Directors or Compensation Committee. No shares of stock will be issued at the time a Restricted Stock Unit is granted, and BioTime will not be required to set aside a fund for the payment of any such award. A recipient of Restricted Stock Units will have no voting rights with respect to the Restricted Stock Units. Upon the expiration of the restrictions applicable to a Restricted Stock Unit, BioTime will either issue to the recipient, without charge, one common share per Restricted Stock Unit or cash in an amount equal to the fair market value of one common share.

The following table summarizes consolidated stock-based compensation expense, including equity awards by privately-held consolidated subsidiaries, related to stock options and other equity awards for the years ended December 31, 2016, 2015, and 2014, which was allocated as follows (in thousands):

	Year Ended December 31,
	2016		2015		2014
Research and Development	$	2,608	$	3,267	$	1,310
General and Administrative		5,343		7,783		3,145
Total stock-based compensation expense	$	7,951	$	11,050	$	4,455

As of December 31, 2016, total unrecognized compensation costs related to unvested stock options under BioTime’s 2002 Plan and 2012 Plan was $6 million, which is expected to be recognized as expense over a weighted average period of approximately 2.81 years.

The weighted-average estimated fair value of stock options granted under BioTime’s 2002 Plan and 2012 Plan during the years ended December 31, 2016, 2015 and 2014 was $1.69, $2.13 and $2.78 per share respectively, using the Black-Scholes Merton model with the following weighted-average assumptions:

	Year Ended December 31,
	2016		2015		2014
Expected life (in years)		5.83		5.62		6.67
Risk-free interest rates		1.45%		1.70%		2.19%
Volatility		61.24%		65.82%		83.20%
Dividend yield		0.00%		0.00%		0.00%

General Option Information

A summary of all equity award activity under BioTime’s 2002 Plan and 2012 Plan for the years ended December 31, 2016, 2015 and 2014 is as follows (in thousands except weighted average exercise price):

	Shares Available for Grant			Number of Options Outstanding			Number of RSUs Outstanding		Weighted Average Exercise Price
January 1, 2014		2,315			4,567			-	$	2.71
Granted under 2012 Plan		(2,170	)		2,170			-		3.54
Exercised		-			(2,060	)		-		0.58
Forfeited/cancelled/expired under 2002 Plan		-			(179	)		-		4.32
Forfeited/cancelled/expired under 2012 Plan		523			(524	)		-		3.72
December 31, 2014		668			3,974			-	$	4.04
Increase in option pool		6,000			-					-
Granted under 2012 Plan		(1,650	)		1,650			-		3.72
Exercised		-			(156	)		-		4.00
Forfeited/cancelled/expired under 2002 Plan		-			(35	)		-		6.72
Forfeited/cancelled/expired under 2012 Plan		239			(239	)		-		3.82
December 31, 2015		5,257			5,194			-	$	3.93
Granted under 2012 Plan		(2,315	)		2,315			-		3.03
RSUs		(200	)		-			100		-
Common stock issued to consultant in lieu of cash		(28	)		-			-		-
Common stock issued to employee for bonuses in lieu of cash		(135	)		-			-		-
Forfeited/cancelled/expired under 2002 Plan		-			(236	)		-		5.17
Forfeited/cancelled/expired under 2012 Plan		315			(315	)		-		3.77
December 31, 2016		2,894			6,958			100	$	3.60

During the year ended December 31, 2016, BioTime issued 81,603 immediately vested common shares in lieu of cash under the 2012 Plan. Those shares are not RSUs but are included in the reduction of approximately 163,000 aggregate shares from the total pool of shares available for grant in the table above. Common shares issued and RSUs granted from the 2012 Plan reduce the shares available for grant by two shares for each common share issued or RSU granted.

Additional information regarding options outstanding under BioTime’s 2002 Plan and 2012 Plan as of December 31, 2016 is as follows (in thousands except exercise prices and weighted average exercise price):

				Options Outstanding					Options Exercisable

Range of Exercise Prices		Number Outstanding		Weighted Avg. Remaining Contractual Life (years)		Weighted Avg. Exercise Price			Number Exercisable		Weighted Avg. Exercise Price
	2.52-3.96		5,349		7.21		$	3.32		2,080		$	3.46
	4.02-4.95		1,429		3.80		$	4.25		1,225		$	4.26
	5.02-8.58		180		0.84		$	6.94		179		$	6.95
$	2.52-8.58		6,958		6.34		$	3.60		3,484		$	3.92

Subsidiary Stock Option Plans

BioTime’s consolidated subsidiaries LifeMap Sciences, LifeMap Solutions, OncoCyte, OrthoCyte, ReCyte Therapeutics, and BioTime Asia have adopted stock option plans that have substantially the same operative provisions (the “Subsidiary Plans”). The LifeMap Sciences stock option plan authorizes the sale of up to 8,000,000 shares of LifeMap Sciences common stock, the LifeMap Solutions stock option plan authorizes the sale of up to 18,667 shares of LifeMap Solutions common stock, the OncoCyte stock option plan authorizes the sale of up to 4,000,000 shares of OncoCyte common stock, the BioTime Asia stock option plan authorizes the sale of up to 1,600 BioTime Asia ordinary shares, and the OrthoCyte and ReCyte Therapeutics stock option plans each authorize the sale of up to 4,000,000 shares of the applicable subsidiary’s common stock, through the exercise of stock options or under restricted stock purchase agreements. Cell Cure also has a stock option plan that authorizes the sale of 125,363 ordinary shares through the exercise of stock options.

No options may be granted under a Subsidiary Plan more than ten years after the date upon which the Subsidiary Plan was adopted by the subsidiary’s Board of Directors, and no options granted under a Subsidiary Plan may be exercised after the expiration of ten years from the date of grant. Under a Subsidiary Plan, options to purchase common stock may be granted to employees, directors and certain consultants at exercise prices not less than the fair market value of the common stock as of the date of grant, subject to certain limited exceptions for options granted in substitution of other options. Options may be fully exercisable immediately, or may be exercisable according to a schedule or conditions specified by the subsidiary’s Board of Directors or its Compensation Committee. Generally, subsidiary stock options have service related vesting conditions based on the continued performance of services for the subsidiary. The Subsidiary Plans also permit the subsidiaries to award restricted stock for services rendered or to sell common stock to employees subject to vesting provisions under restricted stock agreements that provide for forfeiture of unvested shares upon the occurrence of specified events. A subsidiary may permit employees or consultants, but not officers or directors, who purchase stock under restricted stock purchase agreements, to pay for their shares by delivering a promissory note that is secured by a pledge of their shares. As of December 31, 2016, only stock options have been issued under the Subsidiary Plans.

A summary of OncoCyte’s Stock Option Plan activity follows (in thousands except weighted average exercise price):

	Shares Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
January 1, 2014		1,250			2,750		$	0.76
Options forfeited/cancelled		28			(28	)		1.00
December 31, 2014		1,278			2,722		$	0.76
Increase in option pool		4,000			-			-
Options granted		(2,875	)		2,875			1.10
Options exercised		-			(6	)		0.67
Options forfeited/cancelled		1,121			(1,121	)		0.79
2 for 1 reverse stock split		(1,762	)		(2,235	)		2.02
Options granted after reverse stock split		(10	)		10			3.60
Options forfeited/cancelled after reverse stock split		5			(5	)		2.00
December 31, 2015		1,757			2,240		$	2.94
Options granted		(962	)		962			3.58
Options exercised		-			(100	)		2.19
Options forfeited/cancelled		35			(35	)		2.03
Options expired		50			(50	)		2.00
December 31, 2016		880			3,017		$	2.52

A summary of OrthoCyte’s Stock Option Plan activity follows (in thousands except weighted average exercise price):

	Shares Available for Grant		Number of Options Outstanding			Weighted Average Exercise Price
December 31, 2014⁽¹⁾		1,355		2,645		$	0.08
Options forfeited/cancelled		16		(16	)		0.07
December 31, 2015		1,371		2,629		$	0.08
Options forfeited/cancelled		1,329		(1,329	)		0.10
December 31, 2016		2,700		1,300		$	0.06

(1) There was no grant activity during 2014.

A summary of ReCyte’s Stock Option Plan activity follows (in thousands except weighted average exercise price):

	Shares Available for Grant		Number of Options Outstanding			Weighted Average Exercise Price
December 31, 2014⁽¹⁾		2,710		1,290		$	2.05
Options forfeited/cancelled		11		(11	)		2.05
December 31, 2015		2,721		1,279		$	2.05
Options forfeited/cancelled		29		(29	)		2.05
December 31, 2016		2,750		1,250		$	2.05

(1) There was no grant activity during 2014.

A summary of LifeMap Sciences’ Equity Incentive Plan activity follows (in thousands except weighted average exercise price):

	Shares Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
January 1, 2014		413			1,929		$	1.49
Options forfeited/cancelled		58			(58	)		1.48
December 31, 2014		471			1,871		$	1.48
Options granted		(131	)		131			1.92
Options forfeited/cancelled		207			(207	)		1.79
December 31, 2015		547			1,795		$	1.47
Options granted		(20	)		20			2.25
Options forfeited/cancelled		219			(219	)		1.72
December 31, 2016		746			1,596		$	1.44

A summary of LifeMap Solutions’ Equity Incentive Plan activity follows (in thousands except weighted average exercise price):

	Options Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
Option pool added upon incorporation		19			-		$	0.00
Options granted		(13	)		13			500.00
December 31, 2014		6			13		$	500.00
Options granted		(2	)		2			500.00
Options forfeited/cancelled		1			(1	)		500.00
December 31, 2015		5			14		$	500.00
Options granted		(2	)		2			500.00
Options forfeited/cancelled		4			(4	)		500.00
December 31, 2016		7			12		$	500.00

A summary of Cell Cure’s 2007 Employee Share Ownership and Option Plan and 2016 Share Option Plan activity follows (in thousands except weighted average exercise price):

	Options Available for Grant			Number of Options Outstanding		Weighted Average Exercise Price⁽²⁾
December 31, 2015⁽¹⁾		2			12	$	23.93
Increase to option under 2016 Share Option Plan		111			-		-
Options granted		(69	)		69		40.00
December 31, 2016		44			81	$	38.00

(1)

There was no grant activity during 2014 and 2015.

(2)

Cell Cure Neurosciences Share Option Plan US dollar exercise price shown is approximated based on the conversion rate between the US dollar and the New Israeli Shekel, NIS, at the time of grant. The exercise price is denominated in NIS.

BioTime Asia had 1,300 stock options available for future grants and 300 stock options outstanding, with a weighted average exercise price of $0.01 per share as of December 31, 2016.

Commitments and Contingencies [Abstract]

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies

11. Commitments and Contingencies

Alameda Lease

On December 10, 2015, BioTime entered into a lease for approximately 30,795 square feet of rentable space in two buildings located in an office park in Alameda, California (the “New Alameda Lease”). The term of the New Alameda Lease is seven years and BioTime has an option to renew the term for an additional five years. BioTime moved into the facility and the term of the New Alameda Lease commenced effective February 1, 2016.

The landlord provided BioTime with an initial tenant improvement allowance of $1.4 million that was applied to the construction of improvements of the leased premises, primarily for the research and development facilities. BioTime utilized the tenant improvement allowance to complete the leasehold improvements as of June 1, 2016 (see Note 5). The lease liability payments are included in the base rent payments to the landlord and the $1.4 million due to the landlord as of December 31, 2016, will be amortized using the effective interest method over the lease term.

Base rent under the New Alameda Lease commenced on February 1, 2016 at $64,670 per month, and will increase by approximately 3% annually on every February 1 thereafter during the lease term. The lease payments allocated to the landlord liability are amortized as debt service on that liability over the lease term.

Total base lease payments, inclusive of the lease liability, under the New Alameda Lease per the lease agreement for the years ending after December 31, 2016 are shown below (in thousands):

Years Ending December 31,	Minimum Lease Payments
2017	$	797
2018		822
2019		844
2020		870
2021		896
Thereafter		1,002
Total	$	5,231

In addition to base rent, BioTime will pay a pro rata portion of increases in certain expenses, including real property taxes, utilities (to the extent not separately metered to the leased space) and the landlord’s operating expenses, over the amounts of those expenses incurred by the landlord during 2017. As security for the performance of its obligations under the New Alameda Lease, BioTime provided the landlord with an initial security deposit of approximately $847,000, which will be reduced by $423,000 after the first twenty-four months of the lease term, and further reduced by an additional $346,000 after the first thirty-six months of the lease term, by applying those amounts to future rent payment obligations under the lease, if BioTime is not in default under the Lease.

BioTime also currently pays $5,050 per month for the use of office space in New York City, which is made available to BioTime by one of its directors at his cost for use in conducting meetings and other business affairs.

Cell Cure Lease

Cell Cure has leased approximately 1,128 square meters of office and laboratory space in Jerusalem, Israel under a lease that expires between May 30, 2019 and December 31, 2020, with two additional options to extend the lease for 5 years each. Base monthly rent is approximately NIS 55,218 (approximately US $14,400 per month). In addition to base rent, Cell Cure pays a pro rata share of real property taxes and certain costs related to the operation and maintenance of the building in which the leased premises are located.

Rent expense totaled $1.5 million, $2.1 million, and $2.0 million for the years ended December 31, 2016, 2015, and 2014, respectively, included in the consolidated statements of operations.

Future minimum annual lease payments under the various operating leases, including the New Alameda Lease noted above, and capital leases, for the years ending after December 31, 2016 are as follows (in thousands):

Year Ending December 31,	Minimum lease payments⁽¹⁾		Capital lease payments
2017	$	1,098	$	202
2018		1,045		217
2019		1,042		93
2020		1,048		-
2021		897		-
Thereafter		1,002		-
Total	$	6,132	$	512

(1)

Includes the lease of our principal office and laboratory facilities in Alameda, California, including the lease liability, leases of the offices and laboratory facilities of LifeMap Sciences, Cell Cure and other operating leases of lab equipment.

Litigation – General

BioTime will be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When BioTime is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, BioTime will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, BioTime discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. BioTime is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations.

Employment Contracts

BioTime has entered into employment agreements with certain executive officers. Under the provisions of the agreements, BioTime may be required to incur severance obligations for matters relating to changes in control, as defined in the agreements, and involuntary terminations.

Indemnification

In the normal course of business, BioTime may provide indemnifications of varying scope under BioTime’s agreements with other companies or consultants, typically BioTime’s clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, BioTime will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of BioTime’s products and services. Indemnification provisions could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to BioTime products and services. The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particular research, development, services, or license agreement to which they relate. The potential future payments BioTime could be required to make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, BioTime has not been subject to any claims or demands for indemnification. BioTime also maintains various liability insurance policies that limit BioTime’s financial exposure. As a result, BioTime believes the fair value of these indemnification agreements is minimal. Accordingly, BioTime has not recorded any liabilities for these agreements as of December 31, 2016 and 2015.

Royalty obligations and license fees

BioTime and its subsidiaries or affiliates are parties to certain licensing agreements with research institutions, universities and other parties for the rights to use those licenses and other intellectual property in conducting research and development activities. These licensing agreements provide for the payment of royalties by BioTime or the applicable party to the agreement on future product sales, if any. In addition, in order to maintain these licenses and other rights during the product development, BioTime or the applicable party to the contract must comply with various conditions including the payment of patent related costs and annual minimum maintenance fees. Annual minimum maintenance fees are approximately $140,000 to $160,000 per year. The research and development risk for these products is significant. License fees and related expenses under these agreements were $180,000, 282,000 and $432,000 for the years ended December 31, 2016, 2015 and 2014, respectively.

Grants

BioTime accounts for grants received to perform research and development services in accordance with ASC 730-20, Research and Development Arrangements, which requires an assessment at the inception of the grant whether the grant is a liability or a contract to perform research and development services for others. If the company receiving the grant is obligated to repay the grant funds to the grantor regardless of the outcome of the research and development activities, then the company is required to estimate and recognize that liability. Alternatively, if the company receiving the grant is required to repay the grant funds only if the research and development activities are successful, then the grant agreement is accounted for as a contract to perform research and development services for others. In this case, the grant payments are recognized as income when the related research and development expense is incurred.

Under the terms of the grant agreement between Cell Cure and Israel Innovation Authority, or the IIA (formerly the Office of the Chief Scientist of Israel) of the Ministry of Economy and Industry, for the development of OpRegen^®, Cell Cure will be required to pay royalties on future product sales, if any, up to the amounts received from the IIA, plus interest indexed to LIBOR. Cell Cure’s research and product development activities under the grant are subject to substantial risks and uncertainties, and performed on a best efforts basis. As a result, Cell Cure is not required to make any payments under the grant agreement unless it successfully commercializes OpRegen^®. Accordingly, pursuant to ASC 730-20, the Cell Cure grant is considered a contract to perform research and development services for others and grant income is recognized as the related research and development expenses are incurred.

Israeli law pertaining to such government grants contain various conditions, including substantial penalties and restrictions on the transfer of intellectual property, or the manufacture, or both, of products developed under the grant outside of Israel, as defined by the IIA.

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Taxes [Abstract]

Income Taxes

12. Income Taxes

BioTime adopted early the provisions of Accounting Standards Update, ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, on a retrospective basis and due to the full valuation allowance on its deferred tax assets for all periods presented. The adoption of ASU 2015-17 did not have any impact on the consolidated financial statements.

The primary components of the deferred tax assets and liabilities at December 31, 2016 and 2015 were as follows (in thousands):

Deferred tax assets/(liabilities):	2016			2015
Net operating loss carryforwards	$	78,116		$	78,268
Research and development and other credits		7,645			8,331
Patents and licenses		(67	)		(6,860	)
Equity method investments		(40,258	)		(1,333	)
Stock options		1,529			670
Other, net		2,248			(263	)
Total		49,213			78,813
Valuation allowance		(49,213	)		(78,813	)
Net deferred tax liabilities	$	-		$	-

Income taxes differed from the amounts computed by applying the U.S. federal income tax of 34% to pretax losses from operations as a result of the following:

	Year Ended December 31,
	2016		2015		2014
Computed tax benefit at federal statutory rate		34%		34%		34%
Research and development and other credits		(3%)		2%		3%
Permanent differences		2%		(4%)		(1%)
Change in valuation allowance		(63%)		(34%)		(24%)
State tax benefit, net of effect on federal income taxes		24%		10%		3%
Foreign rate differential		6%		(1%)		(1%)
		-%		7%		14%

As of December 31, 2016, BioTime has net operating loss carryforwards of approximately $171.1 million for federal purposes. Of this amount, $22.7 million is attributable to LifeMap Sciences, and $30.6 million is attributable to Oncocyte. As BioTime, LifeMap Sciences and OncoCyte file separate federal income tax returns, their respective net operating loss carryforwards may not be used to offset each other’s taxable income. As of December 31, 2016, BioTime has net operating losses of $95 million for state tax purposes. Of this amount, $15.1 is attributable to OncoCyte. Historically, both LifeMap Sciences and OncoCyte have been included in the combined California tax return with BioTime. As a result of the OncoCyte Deconsolidation on February 17, 2017 (see Note 16), OnCoyte will file a separate California return for tax year 2017. Accordingly, the California net operating loss carryforwards attributable to OncoCyte will not be available to BioTime or LifeMap Sciences. The federal and state net operating losses expire in varying amounts between 2018 and 2036. As of December 31, 2016, BioTime’s subsidiaries have foreign net operating loss carryforwards of approximately $58.5 million which carry forward indefinitely.

As of December 31, 2016, BioTime has research tax credit carryforwards for federal and state tax purposes of $3.8 million and $3.9 million, respectively. The federal tax credits expire between 2018 and 2036, while the state tax credits have no expiration date.

Although the Asterias Deconsolidation was not a taxable transaction to BioTime and did not result in a tax payment obligation, the $49.0 million gain on the Asterias Deconsolidation generated a deferred tax liability that was fully offset by BioTime’s net operating losses. Subsequent to the Asterias Deconsolidation, an unrealized gain of $34.3 million was recorded on the Asterias shares during the year ended December 31, 2016, which was fully offset by available net operating losses and the corresponding release of BioTime’s valuation allowance on deferred tax assets. Accordingly, BioTime did not record any provision or benefit for income taxes for the year ended December 31, 2016. The deferred tax liability generated by the Asterias shares BioTime holds are a source of taxable income as prescribed by ASC 740-10-30-17.

BioTime and Asterias completed certain transactions under a Cross-License Agreement and Share Transfer Agreement on February 16, 2016 pursuant to which BioTime transferred certain assets to Asterias. The asset transfer was a taxable transaction to BioTime generating a taxable gain of approximately $3.1 million. BioTime has sufficient current year losses from operations to offset the entire gain resulting in no income taxes due. As the transfer of assets and the resulting taxable gain was due to a direct effect of transations between a parent company, BioTime, and its then subsidiary, Asterias, BioTime recorded the tax effects of this gain through equity in accordance with ASC 740-20-45-11(g) with a corresponding release of the valuation allowance.

A deferred income tax benefit of $4.5 million was recorded for the year ended December 31, 2015, of which $4.8 million was related to the federal benefit and $290,000 was related to state tax expense. A deferred income tax benefit of $7.4 million was recorded for the year ended December 31, 2014, of which $5.2 million of the benefit was related to federal and $2.2 million was related to state taxes. The deferred tax benefits recorded in 2015 and 2014 were wholly attributable Asterias.

A valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax assets will not be realized. BioTime established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets, including foreign net operating losses generated by its subsidiaries.

On December 31, 2015, BioTime distributed 4.7 million shares of OncoCyte common stock to its shareholders on a pro rata basis. The distribution was accounted for as a dividend in kind for financial reporting purposes. For income tax purposes, the distribution is treated as if BioTime had sold the shares at their fair market value, resulting in a taxable gain to BioTime of approximately $7.4 million. As part of the distribtuion of OncoCyte common stock in December 2015, Asterias also recognized a taxable gain $819,000. Asterias has sufficient current year losses from operations to offset the entire taxable gain resulting in no income taxes due. As the distribution was treated as a dividend in kind for financial reporting purposes, BioTime recorded the tax effect of the gain in equity instead of the tax provision in accordance ASC 740-20-45-11(g). BioTime had sufficient current year losses from operations to offset the entire taxable gain resulting in no income taxes due.

During 2015, OncoCyte sold 259,712 BioTime common shares in open market transactions that resulted in a taxable gain of $815,000. This taxable gain was fully offset by current operating losses resulting in no income taxes due from the sale.

In connection with the above transactions related to the taxable gains, BioTime and subsidiaries utilized approximately $9.1 million in net operating loss carryforwards with a corresponding release of the valuation allowance recorded through equity in accordance with ASC 740-20-45-11(g).

Internal Revenue Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can be offset by net operating loss (“NOL”) carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a control change, a loss corporation cannot deduct NOL carryforwards in excess of the Section 382 Limitation. Due to these “change in ownership” provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods.

BioTime files a U.S. federal income tax return as well as various state and foreign income tax returns. In general, BioTime is no longer subject to tax examination by major taxing authorities for years before 2012. Although the statute is closed for purposes of assessing additional income and tax in these years, the taxing authorities may still make adjustments to the net operating loss and credit carryforwards used in open years. Therefore, the statute should be considered open as it relates to the net operating loss and credit carryforwards.

BioTime's practice is to recognize interest and penalties related to income tax matters in tax expense. As of December 31, 2016 and 2015, BioTime has no accrued interest and penalties. BioTime may be subject to potential examination by U.S. federal, U.S. states or foreign jurisdiction authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, U.S. state and foreign tax laws. BioTime's management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

Segment Information	12 Months Ended
Segment Information	Dec. 31, 2016
Segment Information [Abstract]
Segment Information	13. Segment Information BioTime’s executive management team, as a group, represents the entity’s chief operating decision makers. BioTime’s executive management team views BioTime’s operations as one segment that includes, the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery, and products for human embryonic stem cell research. As a result, the financial information disclosed materially represents all of the financial information related to BioTime’s sole operating segment.

Enterprise-wide Disclosures [Abstract]

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Enterprise-wide Disclosures

12 Months Ended

Dec. 31, 2016

Enterprise-wide Disclosures

14. Enterprise-wide Disclosures

Geographic Area Information

Total revenues, including license fees, royalties, grant income, and other revenues by geographic area are based on the country of domicile of the licensee or grantor (in thousands):

	Revenues for the Year Ended December 31,
Geographic Area	2016		2015		2014
Domestic	$	4,497	$	5,976	$	3,586
Asia		1,426		1,060		1,658
Total revenues	$	5,923	$	7,036	$	5,244

The composition of BioTime’s long-lived assets, consisting of property, plant and equipment, net, between those in the United States and in foreign countries is set forth below (in thousands):

	2016⁽¹⁾		2015
Domestic	$	3,418	$	7,132
Foreign		2,111		407
Total	$	5,529	$	7,539

(1) Reflects the effect of the Asterias Deconsolidation.

Assets in foreign countries principally include laboratory equipment and leasehold improvements in Israel.

Major Sources of Revenues

The following table shows the sources of BioTime’s revenues, as a percentage of total revenues, that were recognized during the years ended December 31, 2016, 2015, and 2014:

	Revenues for the Year Ended December 31,
Sources of Revenues	2016		2015		2014
CIRM grant income		38.0%		42.7%		19.7%
NIH grant income		-%		6.5%		12.5%
IIA (formerly OCS) grant income (Cell Cure, Israel)		24.0%		14.4%		31.3%
Subscriptions, advertising and other (various customers) ⁽¹⁾		35.0%		29.4%		32.5%
Other ⁽¹⁾		3.0%		7.0%		4.0%

(1)

No individual customer greater than 5% of total revenues.

During 2016, BioTime received $972,000 and recognized $668,000 (net of $304,000 in royalty and commission fees) in net subscription and advertisement revenues through LifeMap Sciences, an online database business primarily related to its GeneCards^® database. During 2015, BioTime received $1,357,000 and recognized $679,000 (net of $678,000 in royalty and commission fees) in net subscription and advertisement revenues through LifeMap Sciences.

Selected Quarterly Financial Information (UNAUDITED)

12 Months Ended

Dec. 31, 2016

Selected Quarterly Financial Information (UNAUDITED) [Abstract]

Selected Quarterly Financial Information (UNAUDITED)

15. Selected Quarterly Financial Information (UNAUDITED, in thousands, except per share data)

BioTime has derived this data from the unaudited consolidated interim financial statements that, in BioTime’ s opinion, have been prepared on substantially the same basis as the audited consolidated financial statements contained herein and include all normal recurring adjustments necessary for a fair presentation of the financial information for the periods presented. These unaudited consolidated quarterly results should be read in conjunction with the consolidated financial statements and notes thereto included herein. The consolidated operating results in any quarter are not necessarily indicative of the consolidated results that may be expected for any future period.

Year Ended December 31, 2016	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Revenues, net	$	1,848		$	1,171		$	1,441		$	1,103
Operating expenses		25,606			15,574			10,996			12,356
Loss from operations		(23,758	)		(14,403	)		(9,555	)		(11,253	)
Net income (loss) attributable to BioTime, Inc.		(17,112	)		24,549			31,199			(4,945	)

Basic and diluted net income (loss) per share	$	(0.19	)	$	0.26		$	0.30		$	(0.05	)

Year Ended December 31, 2015
Revenues, net	$	1,000		$	1,749		$	1,874		$	1,306
Operating expenses		14,502			15,245			18,978			23,013
Loss from operations		(13,502	)		(13,496	)		(17,104	)		(21,707	)
Net loss attributable to BioTime, Inc.⁽¹⁾		(10,167	)		(9,691	)		(13,626	)		(13,507	)

Basic and diluted net loss per share	$	(0.13	)	$	(0.12	)	$	(0.18	)	$	(0.16	)

(1)

Net of $4.5 million of deferred income tax benefits for 2015, entirely attributable to Asterias.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2016
Subsequent Event [Abstract]
Subsequent Events	16. Subsequent Events During February 2017, BioTime sold 7,453,704 common shares in an underwritten public offering. The offering price to the public was $2.70 per share and net proceeds to BioTime were approximately $18.7 million, after deducting underwriting discounts, commissions and expenses related to the financing. On February 17, 2017, certain of OncoCyte investors exercised 625,000 Offering Warrants at an exercise price of $3.25 per warrant for total exercise cash proceeds of $2.0 million (the “Warrant exercise”). The Offering Warrants had been issued as part of OncoCyte’s financing that was completed on August 29, 2016 (see Note 9). In order to induce the investors to complete the Warrant exercise and, in conjunction with the Warrant exercise, OncoCyte issued new warrants to those investors (the “New Warrants”). Certain investors received 200,000 New Warrants with an exercise price of $5.50 per warrant share and the other investor received 212,500 New Warrants with an exercise of $3.25 per warrant share. The New Warrants are exercisable at any time for five years from February 17, 2017. As a result of the issuance of 625,000 shares of OncoCyte common stock in the Warrant exercise, as of February 17, 2017, BioTime owned less than 50% of the OncoCyte outstanding common stock. Under GAAP, loss of control of a subsidiary is deemed to have occurred when, among other things, a parent company owns less than a majority of the outstanding common stock of the subsidiary, lacks a controlling financial interest in the subsidiary, and is unable to unilaterally control the subsidiary through other means such as having the ability or being able to obtain the ability to elect a majority of the subsidiary’s Board of Directors. BioTime determined that all of these loss of control factors were present with respect to OncoCyte on February 17, 2017. Accordingly, BioTime has deconsolidated OncoCyte’s financial statements and results of operations from BioTime, effective February 17, 2017, in accordance with ASC, 810-10-40-4(c), Consolidation.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2016

Summary of Significant Accounting Policies [Abstract]

Going concern assessment

Revenue recognition

Cash and cash equivalents

Restricted cash

Trade accounts and grants receivable, net

Concentrations of credit risk

Fair value measurements

Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value.

Equity method accounting for Asterias, at fair value

Available for sale securities in foreign investments

Long-lived intangible assets

Impairment of long-lived assets

Treasury stock

Accounting for warrants

Investments in Common Stock of Privately Held Companies

Cost of sales

Reclassifications

Research and development

General and administrative

Foreign currency translation and other comprehensive loss, foreign currency transaction gains and losses

Income taxes

Stock-based compensation

Net income or loss per share

Recently Issued Accounting Pronouncements

Organization, Basis of Presentation and Liquidity (Tables)

12 Months Ended

Dec. 31, 2016

Organization, Basis of Presentation and Liquidity [Abstract]

BioTime's ownership of outstanding shares of its subsidiaries

The following table reflects BioTime’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its operating subsidiaries as of December 31, 2016.

Subsidiary	Field of Business	BioTime Ownership	Country
Cell Cure Neurosciences Ltd.	Products to treat age-related macular degeneration	62.5%(1)	Israel
ES Cell International Pte. Ltd.	Stem cell products for research, including clinical grade cell lines produced under cGMP	100%	Singapore
LifeMap Sciences, Inc.	Biomedical, gene, disease, and stem cell databases and tools	77.9%	USA
LifeMap Sciences, Ltd.	Biomedical, gene, disease, and stem cell databases and tools	(2)	Israel
LifeMap Solutions, Inc.	Mobile health software	(2)	USA
OncoCyte Corporation (3)	Cancer diagnostics	51.1%	USA
OrthoCyte Corporation	Developing bone grafting products for orthopedic diseases and injuries	100%	USA
ReCyte Therapeutics, Inc.	Research and development involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders, ischemic conditions and brown adipocytes for type-2 diabetes and obesity	94.8%	USA

(1)

Includes shares owned by BioTime and ES Cell International Pte. Ltd.

(2)

LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.

(3)

See Note 16. Beginning February 17, 2017, BioTime deconsolidated OncoCyte and OncoCyte is no longer a subsidiary of BioTime as of that date.

Equity Method Accounting for Common Stock of Asterias, at fair value (Tables)

12 Months Ended

Dec. 31, 2016

Equity Method Accounting for Common Stock of Asterias, at fair value [Abstract]

Condensed results of operations and condensed balance sheet information

The condensed results of operations and condensed balance sheet information of Asterias are summarized below (in thousands):

	For the Year Ended December 31, 2016 ⁽¹⁾
Condensed Statements of Operations ⁽¹⁾:
Total revenue	$	6,954
Gross profit		6,826
Loss from operations		(34,123	)
Net loss	$	(35,038	)

	December 31, 2016		December 31, 2015
Condensed Balance Sheet information ⁽²⁾:
Current assets	$	36,990	$	29,789
Noncurrent assets		24,020		27,445
	$	61,010	$	57,234

Current liabilities	$	6,051	$	4,980
Noncurrent liabilities		12,930		7,155
Stockholders’ equity		42,029		45,099
	$	61,010	$	57,234

(1)

(2)

	For the Period January 1, 2016 through May 12, 2016			Year Ended December 31, 2015			Year Ended December 31, 2014
Total revenue	$	2,354		$	3,582		$	1,224
Gross profit		2,301			3,314			1,129
Loss from operations		(13,944	)		(21,908	)		(17,461	)
Net loss	$	(13,113	)	$	(15,003	)	$	(10,097	)

Property, plant and equipment, net (Tables)

12 Months Ended

Dec. 31, 2016

Property, plant and equipment, net [Abstract]

Intangible assets future amortization expense

At December 31, 2016 and 2015, property, plant and equipment were comprised of the following (in thousands):

	December 31,
	2016(1)			2015
Equipment, furniture and fixtures	$	4,718		$	5,274
Leasehold improvements		3,791			5,623
Construction in progress		-			93
Accumulated depreciation and amortization		(2,980	)		(3,451	)
Property and equipment, net	$	5,529		$	7,539

(1)

Reflects the effect of the Asterias Deconsolidation.

Intangible assets, net (Tables)

12 Months Ended

Dec. 31, 2016

Intangible assets, net [Abstract]

Intangible assets

At December 31, 2016 and 2015, intangible assets, primarily consisting of acquired patents and accumulated amortization were as follows (in thousands):

	December 31,
	2016⁽¹⁾			2015
Intangible assets	$	25,703		$	52,563
Accumulated amortization		(15,497	)		(18,971	)
Intangible assets, net	$	10,206		$	33,592

(1)	Reflects the effect of the Asterias Deconsolidation.

Amortization of intangible assets for periods subsequent to December 31, 2016 is as follows (in thousands):

Year Ended December 31,	Amortization Expense
2017	$	2,570
2018		2,570
2019		2,571
2020		1,794
2021		537
Thereafter		164
Total	$	10,206

Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2016

Shareholders' Equity [Abstract]

Activity related to warrants

BioTime has issued warrants to purchase its common shares. Activity related to warrants in 2016 and 2015 is presented in the table below (in thousands, except price per share):

	Number of Warrant Shares			Per Share Exercise Price		Weighted Average Exercise Price
Outstanding, January 1, 2014		9,752		$	5.00-10.00	$	5.29
Exercised in 2014		(557	)		10.00		10.00
Outstanding, December 31, 2014		9,195		$	5.00	$	5.00
Exercised in 2015		(4	)		5.00		5.00
Warrant adjustment⁽¹⁾		919
Outstanding, December 31, 2015		10,110		$	4.55	$	4.55
Expired in 2016		(715	)		4.55		4.55
Outstanding, December 31, 2016⁽²⁾		9,395		$	4.55	$	4.55

(1)

The number of shares issuable upon the exercise of the warrants was adjusted as a result of the distribution of OncoCyte common stock to BioTime shareholders during December 2015.

(2)

The 9,394,862 outstanding warrants will expire, if unexercised, beginning June 5, 2018 through September 30, 2018.

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Stock Option Plans (Tables)

12 Months Ended

Dec. 31, 2016

Summary of stock option activity

	Year Ended December 31,
	2016		2015		2014
Research and Development	$	2,608	$	3,267	$	1,310
General and Administrative		5,343		7,783		3,145
Total stock-based compensation expense	$	7,951	$	11,050	$	4,455

Schedule of weighted average assumptions to calculate fair value of stock options

	Year Ended December 31,
	2016		2015		2014
Expected life (in years)		5.83		5.62		6.67
Risk-free interest rates		1.45%		1.70%		2.19%
Volatility		61.24%		65.82%		83.20%
Dividend yield		0.00%		0.00%		0.00%

Additional information regarding options outstanding

				Options Outstanding					Options Exercisable

Range of Exercise Prices		Number Outstanding		Weighted Avg. Remaining Contractual Life (years)		Weighted Avg. Exercise Price			Number Exercisable		Weighted Avg. Exercise Price
	2.52-3.96		5,349		7.21		$	3.32		2,080		$	3.46
	4.02-4.95		1,429		3.80		$	4.25		1,225		$	4.26
	5.02-8.58		180		0.84		$	6.94		179		$	6.95
$	2.52-8.58		6,958		6.34		$	3.60		3,484		$	3.92

2002 Plan and 2012 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of share-based compensation, employee stock purchase plan, activity

	Shares Available for Grant			Number of Options Outstanding			Number of RSUs Outstanding		Weighted Average Exercise Price
January 1, 2014		2,315			4,567			-	$	2.71
Granted under 2012 Plan		(2,170	)		2,170			-		3.54
Exercised		-			(2,060	)		-		0.58
Forfeited/cancelled/expired under 2002 Plan		-			(179	)		-		4.32
Forfeited/cancelled/expired under 2012 Plan		523			(524	)		-		3.72
December 31, 2014		668			3,974			-	$	4.04
Increase in option pool		6,000			-					-
Granted under 2012 Plan		(1,650	)		1,650			-		3.72
Exercised		-			(156	)		-		4.00
Forfeited/cancelled/expired under 2002 Plan		-			(35	)		-		6.72
Forfeited/cancelled/expired under 2012 Plan		239			(239	)		-		3.82
December 31, 2015		5,257			5,194			-	$	3.93
Granted under 2012 Plan		(2,315	)		2,315			-		3.03
RSUs		(200	)		-			100		-
Common stock issued to consultant in lieu of cash		(28	)		-			-		-
Common stock issued to employee for bonuses in lieu of cash		(135	)		-			-		-
Forfeited/cancelled/expired under 2002 Plan		-			(236	)		-		5.17
Forfeited/cancelled/expired under 2012 Plan		315			(315	)		-		3.77
December 31, 2016		2,894			6,958			100	$	3.60

OncoCyte Common Stock Option Plans [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of share-based compensation, employee stock purchase plan, activity

A summary of OncoCyte’s Stock Option Plan activity follows (in thousands except weighted average exercise price):

	Shares Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
January 1, 2014		1,250			2,750		$	0.76
Options forfeited/cancelled		28			(28	)		1.00
December 31, 2014		1,278			2,722		$	0.76
Increase in option pool		4,000			-			-
Options granted		(2,875	)		2,875			1.10
Options exercised		-			(6	)		0.67
Options forfeited/cancelled		1,121			(1,121	)		0.79
2 for 1 reverse stock split		(1,762	)		(2,235	)		2.02
Options granted after reverse stock split		(10	)		10			3.60
Options forfeited/cancelled after reverse stock split		5			(5	)		2.00
December 31, 2015		1,757			2,240		$	2.94
Options granted		(962	)		962			3.58
Options exercised		-			(100	)		2.19
Options forfeited/cancelled		35			(35	)		2.03
Options expired		50			(50	)		2.00
December 31, 2016		880			3,017		$	2.52

A summary of OrthoCyte’s Stock Option Plan activity follows (in thousands except weighted average exercise price):

	Shares Available for Grant		Number of Options Outstanding			Weighted Average Exercise Price
December 31, 2014⁽¹⁾		1,355		2,645		$	0.08
Options forfeited/cancelled		16		(16	)		0.07
December 31, 2015		1,371		2,629		$	0.08
Options forfeited/cancelled		1,329		(1,329	)		0.10
December 31, 2016		2,700		1,300		$	0.06

(1) There was no grant activity during 2014.

ReCyte Therapeutics, Inc. [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of share-based compensation, employee stock purchase plan, activity

A summary of ReCyte’s Stock Option Plan activity follows (in thousands except weighted average exercise price):

	Shares Available for Grant		Number of Options Outstanding			Weighted Average Exercise Price
December 31, 2014⁽¹⁾		2,710		1,290		$	2.05
Options forfeited/cancelled		11		(11	)		2.05
December 31, 2015		2,721		1,279		$	2.05
Options forfeited/cancelled		29		(29	)		2.05
December 31, 2016		2,750		1,250		$	2.05

(1) There was no grant activity during 2014.

LifeMap Sciences, Inc. [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of share-based compensation, employee stock purchase plan, activity

A summary of LifeMap Sciences’ Equity Incentive Plan activity follows (in thousands except weighted average exercise price):

	Shares Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
January 1, 2014		413			1,929		$	1.49
Options forfeited/cancelled		58			(58	)		1.48
December 31, 2014		471			1,871		$	1.48
Options granted		(131	)		131			1.92
Options forfeited/cancelled		207			(207	)		1.79
December 31, 2015		547			1,795		$	1.47
Options granted		(20	)		20			2.25
Options forfeited/cancelled		219			(219	)		1.72
December 31, 2016		746			1,596		$	1.44

LifeMap Solutions, Inc [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of share-based compensation, employee stock purchase plan, activity

A summary of LifeMap Solutions’ Equity Incentive Plan activity follows (in thousands except weighted average exercise price):

	Options Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
Option pool added upon incorporation		19			-		$	0.00
Options granted		(13	)		13			500.00
December 31, 2014		6			13		$	500.00
Options granted		(2	)		2			500.00
Options forfeited/cancelled		1			(1	)		500.00
December 31, 2015		5			14		$	500.00
Options granted		(2	)		2			500.00
Options forfeited/cancelled		4			(4	)		500.00
December 31, 2016		7			12		$	500.00

Cell Cures Employee Share Ownership and Option Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of share-based compensation, employee stock purchase plan, activity

A summary of Cell Cure’s 2007 Employee Share Ownership and Option Plan and 2016 Share Option Plan activity follows (in thousands except weighted average exercise price):

	Options Available for Grant			Number of Options Outstanding		Weighted Average Exercise Price⁽²⁾
December 31, 2015⁽¹⁾		2			12	$	23.93
Increase to option under 2016 Share Option Plan		111			-		-
Options granted		(69	)		69		40.00
December 31, 2016		44			81	$	38.00

(1)

There was no grant activity during 2014 and 2015.

(2)

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies [Abstract]

Base rent under New Alameda lease

Total base lease payments, inclusive of the lease liability, under the New Alameda Lease per the lease agreement for the years ending after December 31, 2016 are shown below (in thousands):

Years Ending December 31,	Minimum Lease Payments
2017	$	797
2018		822
2019		844
2020		870
2021		896
Thereafter		1,002
Total	$	5,231

Future minimum operating and capital lease payments

Year Ending December 31,	Minimum lease payments⁽¹⁾		Capital lease payments
2017	$	1,098	$	202
2018		1,045		217
2019		1,042		93
2020		1,048		-
2021		897		-
Thereafter		1,002		-
Total	$	6,132	$	512

(1)

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Taxes [Abstract]

Components of Deferred Tax Assets and Liabilities

The primary components of the deferred tax assets and liabilities at December 31, 2016 and 2015 were as follows (in thousands):

Deferred tax assets/(liabilities):	2016			2015
Net operating loss carryforwards	$	78,116		$	78,268
Research and development and other credits		7,645			8,331
Patents and licenses		(67	)		(6,860	)
Equity method investments		(40,258	)		(1,333	)
Stock options		1,529			670
Other, net		2,248			(263	)
Total		49,213			78,813
Valuation allowance		(49,213	)		(78,813	)
Net deferred tax liabilities	$	-		$	-

Income Tax Rate Reconciliation

Income taxes differed from the amounts computed by applying the U.S. federal income tax of 34% to pretax losses from operations as a result of the following:

	Year Ended December 31,
	2016		2015		2014
Computed tax benefit at federal statutory rate		34%		34%		34%
Research and development and other credits		(3%)		2%		3%
Permanent differences		2%		(4%)		(1%)
Change in valuation allowance		(63%)		(34%)		(24%)
State tax benefit, net of effect on federal income taxes		24%		10%		3%
Foreign rate differential		6%		(1%)		(1%)
		-%		7%		14%

Enterprise-wide Disclosures (Tables)

12 Months Ended

Dec. 31, 2016

Enterprise-wide Disclosures [Abstract]

Geographic Area Information

Total revenues, including license fees, royalties, grant income, and other revenues by geographic area are based on the country of domicile of the licensee or grantor (in thousands):

	Revenues for the Year Ended December 31,
Geographic Area	2016		2015		2014
Domestic	$	4,497	$	5,976	$	3,586
Asia		1,426		1,060		1,658
Total revenues	$	5,923	$	7,036	$	5,244

The composition of BioTime’s long-lived assets, consisting of property, plant and equipment, net, between those in the United States and in foreign countries is set forth below (in thousands):

	2016⁽¹⁾		2015
Domestic	$	3,418	$	7,132
Foreign		2,111		407
Total	$	5,529	$	7,539

(1) Reflects the effect of the Asterias Deconsolidation.

Sources of Revenues

The following table shows the sources of BioTime’s revenues, as a percentage of total revenues, that were recognized during the years ended December 31, 2016, 2015, and 2014:

	Revenues for the Year Ended December 31,
Sources of Revenues	2016		2015		2014
CIRM grant income		38.0%		42.7%		19.7%
NIH grant income		-%		6.5%		12.5%
IIA (formerly OCS) grant income (Cell Cure, Israel)		24.0%		14.4%		31.3%
Subscriptions, advertising and other (various customers) ⁽¹⁾		35.0%		29.4%		32.5%
Other ⁽¹⁾		3.0%		7.0%		4.0%

(1)

No individual customer greater than 5% of total revenues.

Selected Quarterly Financial Information (UNAUDITED) (Tables)

12 Months Ended

Dec. 31, 2016

Selected Quarterly Financial Information (UNAUDITED) [Abstract]

Selected Quarterly Financial Information

The consolidated operating results in any quarter are not necessarily indicative of the consolidated results that may be expected for any future period.

Year Ended December 31, 2016	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Revenues, net	$	1,848		$	1,171		$	1,441		$	1,103
Operating expenses		25,606			15,574			10,996			12,356
Loss from operations		(23,758	)		(14,403	)		(9,555	)		(11,253	)
Net income (loss) attributable to BioTime, Inc.		(17,112	)		24,549			31,199			(4,945	)

Basic and diluted net income (loss) per share	$	(0.19	)	$	0.26		$	0.30		$	(0.05	)

Year Ended December 31, 2015
Revenues, net	$	1,000		$	1,749		$	1,874		$	1,306
Operating expenses		14,502			15,245			18,978			23,013
Loss from operations		(13,502	)		(13,496	)		(17,104	)		(21,707	)
Net loss attributable to BioTime, Inc.⁽¹⁾		(10,167	)		(9,691	)		(13,626	)		(13,507	)

Basic and diluted net loss per share	$	(0.13	)	$	(0.12	)	$	(0.18	)	$	(0.16	)

(1)

Net of $4.5 million of deferred income tax benefits for 2015, entirely attributable to Asterias.

Organization, Basis of Presentation and Liquidity, General (Details)	12 Months Ended
	Dec. 31, 2016 Technology Program Sector Subsidiary	Feb. 17, 2017	May 13, 2016	Dec. 31, 2015	Dec. 31, 2014
Organization, Basis of Presentation and Liquidity [Abstract]
Number of platform technologies \| Technology	2
Number of clinical stage programs \| Program	3
Number of primary sectors \| Sector	3
Number of subsidiaries \| Subsidiary	2
Asterias Biotherapeutics, Inc. [Member]
Schedule of Equity Method Investments [Line Items]
Equity method ownership percentage	48.70%		57.10%
Equity method ownership percentage after public offering			48.70%
Asterias Biotherapeutics, Inc. [Member] \| Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Equity method ownership percentage	50.00%
OncoCyte Corporation [Member]
Schedule of Equity Method Investments [Line Items]
Equity method ownership percentage				57.80%	76.50%
OncoCyte Corporation [Member] \| Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Equity method ownership percentage	50.00%
OncoCyte Corporation [Member] \| Subsequent Event [Member] \| Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Equity method ownership percentage		50.00%

Organization, Basis of Presentation and Liquidity, Principles of Consolidation and Liquidity (Details) - USD ($)
$ in Thousands

1 Months Ended

Feb. 15, 2017

Feb. 28, 2017

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Cash, cash equivalents and available for sale securities

Accumulated deficit

$ (196,321)

$ (229,893)

Working capital

17,000

Shareholders' equity

130,508

$ 76,447

$ 62,723

$ 42,261

$ 12,500

Subsequent Event [Member] | Common Stock [Member]

Proceeds from issuance initial public offering

$ 18,700

Cell Cure Neurosciences, Ltd. [Member] | Israel [Member]

ES Cell International Pte. Ltd. [Member] | Singapore [Member]

^[1]

62.50%

LifeMap Sciences, Inc. [Member] | USA [Member]

100.00%

LifeMap Sciences, Ltd. [Member] | Israel [Member]

77.90%

LifeMap Solutions, Inc [Member] | USA [Member]

^[2]

0.00%

OncoCyte Corporation [Member] | USA [Member]

^[2]

0.00%

OrthoCyte Corporation [Member] | USA [Member]

^[3]

51.10%

ReCyte Therapeutics, Inc. [Member] | USA [Member]

100.00%

Schedule of Equity Method Investments [Line Items]

94.80%

[1]	Includes shares owned by BioTime and ES Cell International Pte. Ltd.
[2]	LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.
[3]	See Note 16. Beginning February 17, 2017, BioTime deconsolidated OncoCyte and OncoCyte is no longer a subsidiary of BioTime as of that date.

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	May 13, 2016
Cash and cash equivalents [Abstract]
Money market funds, cash equivalent	$ 16,800,000	$ 35,500,000
Trade accounts and grants receivable, net [Abstract]
Net trade receivable	344,000	754,000
Grants receivable	102,000	324,000
Allowance for doubtful accounts	543,000
Schedule of Equity Method Investments [Line Items]
Write down of investment	$ 3,500,000
Long-lived intangible assets [Abstract]
Intangible asset, useful life	10 years
Foreign currency translation and other comprehensive loss, foreign currency transaction gains and losses [Abstract]
Change in foreign currency translation	$ (106,000)	$ (424,000)	$ 125,000
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average dilutive common shares used to compute diluted net income per common share (in shares)	99,553,000	79,711,000	66,467,000
Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Equity method ownership percentage	20.00%
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years
Common Stock [Member]
Foreign currency translation and other comprehensive loss, foreign currency transaction gains and losses [Abstract]
Change in foreign currency translation	$ 0	$ 0	$ 0
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average dilutive common shares used to compute diluted net income per common share (in shares)	2,030,000
Asterias Biotherapeutics [Member]
Schedule of Equity Method Investments [Line Items]
Equity method ownership percentage	48.70%			57.10%
Asterias Biotherapeutics [Member] \| Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Equity method ownership percentage	50.00%
Alameda Lease [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Certificates deposit	$ 847,000
Treasury Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from computation of diluted loss per share (in shares)		4,472,586	4,893,942
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average dilutive common shares used to compute diluted net income per common share (in shares)	206,000
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average dilutive common shares used to compute diluted net income per common share (in shares)	206,000
Anti-dilutive shares excluded from computation of diluted loss per share (in shares)		5,194,313	3,974,326
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average dilutive common shares used to compute diluted net income per common share (in shares)	9,400,000
Anti-dilutive shares excluded from computation of diluted loss per share (in shares)		10,109,860	9,194,679

Deconsolidation of Asterias (Details) - USD ($) $ in Thousands			12 Months Ended
	Jun. 16, 2016	May 13, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Noncontrolling Interest [Line Items]
Proceeds from sale of stock	$ 16,400
Gain on deconsolidation			$ 49,048	$ 0	$ 0
Common shares, outstanding (in shares)			102,776,539	90,421,554
Asterias Biotherapeutics, Inc. [Member]
Noncontrolling Interest [Line Items]
Number of shares sold (in shares)		5,147,059
Warrants issued to purchase common stock (in shares)		2,959,559
Proceeds from sale of stock		$ 16,200
Number of units available through offerings (in shares)		708,333
Percentage of ownership interest outstanding after offering		48.70%	46.00%
Gain on deconsolidation			$ 49,000
Common shares, outstanding (in shares)			21,700,000

Equity Method Accounting for Common Stock of Asterias, at fair value (Details) - USD ($)
$ in Thousands, shares in Millions

4 Months Ended

12 Months Ended

May 12, 2016

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

May 13, 2016

Fair value on investment

$ 100,039

$ 0

Asterias Biotherapeutics, Inc. [Member]

Schedule of Equity Method Investments [Line Items]

Common stock, outstanding (in shares)

21.7

Fair value on investment

100,000

$ 65,700

Unrealized gains on equity method investment

34,300

Condensed Statements of Operations [Abstract]

Total revenue

$ 2,354

6,954

^[1]

3,582

$ 1,224

Gross profit

2,301

6,826

^[1]

3,314

1,129

Loss from operations

(13,944)

(34,123)

^[1]

(21,908)

(17,461)

Net loss

$ (13,113)

(35,038)

^[1]

(15,003)

$ (10,097)

Condensed Balance Sheet information [Abstract]

Current assets

^[2]

36,990

29,789

Noncurrent assets

^[2]

24,020

27,445

Total assets

^[2]

61,010

57,234

Current liabilities

^[2]

6,051

4,980

Noncurrent liabilities

^[2]

12,930

7,155

Stockholders' equity

^[2]

42,029

45,099

Total liabilities and stockholders' equity

^[2]

$ 61,010

$ 57,234

[1]

[2]

The condensed balance sheet information of Asterias as of December 31, 2016, provided for informational and comparative purposes only, was not included in BioTime's consolidated balance sheet at December 31, 2016 due to the Asterias Deconsolidation on May 13, 2016. The condensed balance sheet information of Asterias as of December 31, 2015, included in the table above, was included in BioTime's consolidated balance sheet at December 31, 2015, after intercompany eliminations.

Property, plant and equipment, net (Details) - USD ($)

12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Accumulated depreciation and amortization

$ (2,980,000)

^[1]

$ (3,451,000)

Property and equipment, net

5,529,000

^[1]

7,539,000

Depreciation and amortization expense

1,180,000

1,078,000

$ 1,051,000

Leasehold Improvements [Abstract]

Leasehold improvements

1,600,000

Equipment Furniture and Fixtures [Member]

Leasehold Improvements [Member]

4,718,000

^[1]

5,274,000

Tenant improvement allowance under lease agreement

3,791,000

^[1]

5,623,000

Leasehold Improvements [Abstract]

1,400,000

Nonreimbursement leasehold improvement from landlord

200,000

Construction in Progress [Member]

Property, Plant Equipment under Capital Leases [Member]

^[1]

93,000

$ 626,000

$ 33,800

[1]	(1) Reflects the effect of the Asterias Deconsolidation.

Intangible assets, net (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Intangible assets, net [Abstract]

Intangible assets

$ 25,703

^[1]

$ 52,563

Accumulated amortization

(15,497)

^[1]

(18,971)

Intangible assets, useful life

$ 10,206

^[1]

33,592

10 years

Amortization of intangible assets

$ 3,577

5,256

$ 7,360

Intangible assets future amortization expense [Abstract]

2,570

2,570

2,571

1,794

537

164

Accounts Payable and Accrued Liabilities [Abstract]

$ 10,206

^[1]

$ 33,592

[1]	Reflects the effect of the Deconsolidation.

Accounts Payable and Accrued Liabilities (Details) - USD ($)
$ in Thousands

Dec. 31, 2016

^[1]

Dec. 31, 2015

Accounts payable

$ 1,593

$ 2,798

Accrued expenses

3,212

5,021

Accrued payroll and bonus

1,904

1,126

Other current liabilities

435

432

Total

$ 7,144

$ 9,377

[1]	Reflects the effect of the Asterias Deconsolidation.

Related Party Transactions (Details)	1 Months Ended		12 Months Ended
Related Party Transactions (Details)	Nov. 30, 2015 USD ($)	Apr. 30, 2015 USD ($)	Dec. 31, 2016 USD ($) ft² $ / shares	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($) Shareholder
Related Party Transaction [Line Items]
Rent per month			$ 5,050
Area of office space (in square feet) \| ft²			900
Principal and accumulated interest			$ 1,757,000	$ 255,000	$ 471,000
Carrying value of convertible debt			1,032,000	324,000
Accounts receivable from affiliates			511,000	0
Cell Cure Neurosciences, Ltd. [Member]
Related Party Transaction [Line Items]
Principal and accumulated interest					$ 471,000
Number of shareholders \| Shareholder					2
Carrying value of convertible debt			1,865,000	324,000
Amount of convertible debt			2,544,000	748,000
Unamortized debt discount			679,000	$ 424,000
Cell Cure Neurosciences, Ltd. [Member] \| Convertible Notes [Member]
Related Party Transaction [Line Items]
Principal and accumulated interest	$ 188,000	$ 66,000	$ 1,757,000
Stated interest rate			3.00%
Conversion price (in dollars per share) \| $ / shares			$ 20.00
Accrued interest is payable period			3 years
Cell Cure Neurosciences, Ltd. [Member] \| Convertible Notes [Member] \| Minimum [Member]
Related Party Transaction [Line Items]
Estimated fair market value (in dollars per share) \| $ / shares			$ 28.00
Intrinsic value (in dollars per share) \| $ / shares			$ 8
Effective annual interest rate			11.00%
Cell Cure Neurosciences, Ltd. [Member] \| Convertible Notes [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Estimated fair market value (in dollars per share) \| $ / shares			$ 40.00
Intrinsic value (in dollars per share) \| $ / shares			$ 20
Effective annual interest rate			23.00%

Shareholders' Equity, Warrants (Details) - Warrants [Member] - $ / shares
shares in Thousands

12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Numbers of Warrant Shares [Roll Forward]

Warrants Outstanding Beginning Balance (in shares)

10,110

9,195

9,752

Exercised (in shares)

(4)

(557)

Warrant adjustment (in shares)

^[1]

919

Expired in 2016 (in shares)

(715)

Warrants Outstanding Ending Balance (in shares)

9,395

^[2]

10,110

9,195

Per share exercise price [Abstract]

Outstanding Beginning Balance (in dollars per share)

$ 4.55

$ 5.00

Exercised (in dollars per share)

5.00

$ 10.00

Expired in 2016 (in dollars per share)

4.55

Outstanding Ending Balance (in dollars per share)

4.55

^[2]

4.55

5.00

Weighted Average Exercise Price [Abstract]

Outstanding Beginning Balance (in dollars per share)

4.55

5.00

5.29

Exercised (in dollars per share)

5.00

10.00

Expired in 2016 (in dollars per share)

4.55

Outstanding Ending Balance(in dollars per share)

$ 4.55

^[2]

$ 4.55

5.00

Minimum [Member]

Per share exercise price [Abstract]

Outstanding Beginning Balance (in dollars per share)

5.00

Maximum [Member]

Per share exercise price [Abstract]

Outstanding Beginning Balance (in dollars per share)

$ 10.00

[1]	The number of shares issuable upon the exercise of the warrants was adjusted as a result of the distribution of OncoCyte common stock to BioTime shareholders during December 2015.
[2]	At December 31, 2016, the 9,394,862 outstanding warrants will expire, if unexercised, beginning June 5, 2018 through September 30, 2018.

Shareholders' Equity, Preferred and Common Shares (Details)								1 Months Ended			12 Months Ended
	Feb. 17, 2017 shares	Feb. 15, 2017 shares	Aug. 29, 2016 USD ($) $ / shares shares	Jul. 16, 2016 shares	Jul. 05, 2016 USD ($) shares	Jun. 16, 2016 USD ($) $ / shares	May 13, 2016 USD ($) shares	Feb. 28, 2017 $ / shares shares	Oct. 31, 2015 USD ($) Investor $ / shares shares	Sep. 30, 2015 USD ($) Shareholder $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2014
Preferred Shares [Abstract]
Preferred shares, shares authorized (in shares)											2,000,000	2,000,000
Preferred shares, shares issued (in shares)											0	0
Preferred shares, shares outstanding (in shares)											0	0
Common Shares [Abstract]
Common shares, authorized (in shares)											150,000,000	150,000,000
Common shares, par value (in dollars per share) \| $ / shares											$ 0	$ 0
Common shares, issued (in shares)											103,396,245	94,894,140
Common shares, outstanding (in shares)											102,776,539	90,421,554
Treasury stock (in shares)											619,706	4,472,586
Purchase price per share (in dollars per share) \| $ / shares						$ 2.39
Common shares, new shares issued (in shares)				7,322,176
Proceeds from sale of stock \| $						$ 16,400,000
Noncontrolling interest \| $											$ 12,580,000	$ 50,631,000
OncoCyte Offering [Member]
Common Shares [Abstract]
Issuance of common stock and warrants (in dollars per share) \| $ / shares			$ 3.25
OncoCyte Offering Warrants [Member]
Common Shares [Abstract]
Warrants to purchase stock (in shares)			1
Warrants exercised period											5 years
Asterias Biotherapeutics [Member]
Common Shares [Abstract]
Common shares, outstanding (in shares)											21,700,000
Proceeds from sale of stock \| $							$ 16,200,000
Number of shares sold (in shares)							5,147,059
Equity method ownership percentage							57.10%				48.70%
Percentage of ownership interest							57.10%				48.70%
Noncontrolling interest \| $											$ 18,300,000
Asterias Biotherapeutics [Member] \| Maximum [Member]
Common Shares [Abstract]
Equity method ownership percentage											50.00%
Percentage of ownership interest											50.00%
OncoCyte Corporation [Member]
Common Shares [Abstract]
Proceeds from sale of stock \| $			$ 9,800,000
Shares distributed to shareholders (in shares)												4,700,000
Shares conversion ratio												20
Reduction in equity method investment \| $												$ 712,000
Equity method ownership percentage												57.80%	76.50%
Taxable gain \| $												$ 7,400,000
Decrease in equity method investment												18.70%
Issuance of common stock and warrants (in shares)			3,246,153
Warrants to purchase common stock (in shares)			1
Percentage of ownership interest												57.80%	76.50%
Noncontrolling interest \| $											$ 4,000,000
OncoCyte Corporation [Member] \| Maximum [Member]
Common Shares [Abstract]
Equity method ownership percentage											50.00%
Percentage of ownership interest											50.00%
OncoCyte Corporation [Member] \| Subsequent Event [Member]
Common Shares [Abstract]
Issuance of common stock and warrants (in shares)	625,000
OncoCyte Corporation [Member] \| Subsequent Event [Member] \| Maximum [Member]
Common Shares [Abstract]
Equity method ownership percentage	50.00%
Percentage of ownership interest	50.00%
Over-Allotment Option [Member]
Common Shares [Abstract]
Common shares, new shares issued (in shares)					1,098,326
Proceeds from sale of stock \| $					$ 2,200,000
BioTime Common Stock [Member]
Common Shares [Abstract]
Number of shares sold (in shares)									1,600,000	2,607,401
Proceeds from sale of shares \| $									$ 5,100,000	$ 8,600,000
Number of shareholders \| Shareholder										3
Price per share (in dollars per share) \| $ / shares									$ 3.19	$ 3.29
BioTime Common Stock [Member] \| Subsequent Event [Member]
Common Shares [Abstract]
Common shares, new shares issued (in shares)		7,453,704						7,453,704
Price per share (in dollars per share) \| $ / shares								$ 2.70
BioTime Common Stock [Member] \| OncoCyte Corporation [Member]
Common Shares [Abstract]
Number of shares sold (in shares)									246,356
Number of investors \| Investor									1
Price per share (in dollars per share) \| $ / shares									$ 3.13
BioTime Common Stock [Member] \| Certain investors [Member]
Common Shares [Abstract]
Number of shares sold (in shares)									6,530,612
Proceeds from sale of shares \| $									$ 20,400,000
Price per share (in dollars per share) \| $ / shares									$ 3.13

Stock Option Plans (Details) - USD ($)	12 Months Ended
Stock Option Plans (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period when options may not be granted or exercised	10 years
Weighted-average estimated fair value of stock options granted (in dollars per share)	$ 0	$ 0
2002 Plan and 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation costs	$ 6
Weighted average recognition period	2 years 9 months 22 days
Weighted-average estimated fair value of stock options granted (in dollars per share)	$ 1.69	$ 2.13	$ 2.78
Weighted-average Assumptions [Abstract]
Expected life	5 years 9 months 29 days	5 years 7 months 13 days	6 years 8 months 1 day
Risk-free interest rates	1.45%	1.70%	2.19%
Volatility	61.24%	65.82%	83.20%
Dividend yield	0.00%	0.00%	0.00%
Shares Available for Grant [Roll Forward]
Increase in option pool (in shares)		6,000,000
Options exercised (in shares)		0	0
Restricted stock issued (in shares)	(200,000)
Number of Options Outstanding [Roll Forward]
Increase in option pool (in shares)		0
Options exercised (in shares)		(156,000)	(2,060,000)
Restricted stock issued (in shares)	100,000
Weighted Average Exercise Price [Roll Forward]
Increase in option pool (in dollars per share)		$ 0
Options exercised (in dollars per share)		$ 4.00	$ 0.58
Shares Available for Grant [Roll Forward]
Beginning of the period (in shares)	5,257,000	668,000	2,315,000
Increase option pool (in shares)		6,000,000
Restricted stock issued (in shares)	(200,000)
Common stock issued to consultant in lieu of cash (in shares)	(28,000)
Common stock issued to employee for bonuses in lieu of cash (in shares)	(135,000)
Exercised (in shares)		0	0
End of the period (in shares)	2,894,000	5,257,000	668,000
Number of Options Outstanding [Roll Forward]
Outstanding, beginning of the period (in shares)	5,194,000	3,974,000	4,567,000
Increase option pool (in shares)		0
Exercised (in shares)		(156,000)	(2,060,000)
Outstanding, end of the period (in shares)	6,958,000	5,194,000	3,974,000
Number of RSUs Outstanding [Roll Forward]
Warrants Outstanding Beginning Balance (in shares)	0
RSUs (in shares)	100,000
Warrants Outstanding Ending Balance (in shares)	100,000	0
Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of the period (in dollars per share)	$ 3.93	$ 4.04	$ 2.71
Increase option pool (in dollars per share)		0
Exercised (in dollars per share)		4.00	0.58
Outstanding end of the period (in dollars per share)	3.60	$ 3.93	$ 4.04
2002 Plan and 2012 Plan [Member] \| 2.52-3.96 [Member]
Additional Information regarding options outstanding [Abstract]
Range of Exercise Prices, Lower Range Limit (in dollars per share)	2.52
Range of Exercise Prices, Upper Range Limit (in dollars per share)	$ 3.96
Number Outstanding (in shares)	5,349,000
Options Outstanding, Weighted Avg. Remaining Contractual Life	7 years 2 months 16 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 3.32
Number Exercisable (in shares)	2,080,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 3.46
2002 Plan and 2012 Plan [Member] \| 4.02-4.95 [Member]
Additional Information regarding options outstanding [Abstract]
Range of Exercise Prices, Lower Range Limit (in dollars per share)	4.02
Range of Exercise Prices, Upper Range Limit (in dollars per share)	$ 4.95
Number Outstanding (in shares)	1,429,000
Options Outstanding, Weighted Avg. Remaining Contractual Life	3 years 9 months 18 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 4.25
Number Exercisable (in shares)	1,225,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 4.26
2002 Plan and 2012 Plan [Member] \| 5.02-8.58 [Member]
Additional Information regarding options outstanding [Abstract]
Range of Exercise Prices, Lower Range Limit (in dollars per share)	5.02
Range of Exercise Prices, Upper Range Limit (in dollars per share)	$ 8.58
Number Outstanding (in shares)	180,000
Options Outstanding, Weighted Avg. Remaining Contractual Life	10 months 2 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 6.94
Number Exercisable (in shares)	179,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 6.95
2002 Plan and 2012 Plan [Member] \| $2.52-$8.58 [Member]
Additional Information regarding options outstanding [Abstract]
Range of Exercise Prices, Lower Range Limit (in dollars per share)	2.52
Range of Exercise Prices, Upper Range Limit (in dollars per share)	$ 8.58
Number Outstanding (in shares)	6,958,000
Options Outstanding, Weighted Avg. Remaining Contractual Life	6 years 4 months 2 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 3.60
Number Exercisable (in shares)	3,484,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 3.92
2002 Plan [Member]
Shares Available for Grant [Roll Forward]
Options expired/forfeited/cancelled (in shares)	0	0	0
Number of Options Outstanding [Roll Forward]
Options forfeited/cancelled/expired (in shares)	(236,000)	(35,000)	(179,000)
Weighted Average Exercise Price [Roll Forward]
Options forfeited/cancelled (in dollars per share)	$ 5.17	$ 6.72	$ 4.32
Shares Available for Grant [Roll Forward]
Forfeited/cancelled/expired (in shares)	0	0	0
Number of Options Outstanding [Roll Forward]
Forfeited/cancelled/expired (in shares)	(236,000)	(35,000)	(179,000)
Weighted Average Exercise Price [Roll Forward]
Forfeited/cancelled/expired (in dollars per share)	$ 5.17	$ 6.72	$ 4.32
2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares reserved for future issuance (in shares)			10,000,000
Period when options may not be granted or exercised			10 years
Common shares vested issued in lieu of cash (in shares)	81,603
Number of shares available for grant (in shares)	163,000
Common shares issued or RSU granted (in shares)	2
Shares Available for Grant [Roll Forward]
Options granted (in shares)	(2,315,000)	(1,650,000)	(2,170,000)
Options expired/forfeited/cancelled (in shares)	315,000	239,000	523,000
Number of Options Outstanding [Roll Forward]
Options granted (in shares)	2,315,000	1,650,000	2,170,000
Options forfeited/cancelled/expired (in shares)	(315,000)	(239,000)	(524,000)
Weighted Average Exercise Price [Roll Forward]
Options granted (in dollars per share)	$ 3.03	$ 3.72	$ 3.54
Options forfeited/cancelled (in dollars per share)	$ 3.77	$ 3.82	$ 3.72
Shares Available for Grant [Roll Forward]
Granted (in shares)	(2,315,000)	(1,650,000)	(2,170,000)
Forfeited/cancelled/expired (in shares)	315,000	239,000	523,000
Number of Options Outstanding [Roll Forward]
Granted (in shares)	2,315,000	1,650,000	2,170,000
Forfeited/cancelled/expired (in shares)	(315,000)	(239,000)	(524,000)
Weighted Average Exercise Price [Roll Forward]
Granted (in dollars per share)	$ 3.03	$ 3.72	$ 3.54
Forfeited/cancelled/expired (in dollars per share)	$ 3.77	$ 3.82	$ 3.72
OncoCyte, OrthoCyte and ReCyte Therapeutics Stock Option Plans [Member]
Additional Information regarding options outstanding [Abstract]
Authorize number of shares under stock option plan (in shares)	4,000,000
BioTime Asia Stock Option Plan [Member]
Additional Information regarding options outstanding [Abstract]
Authorize number of shares under stock option plan (in shares)	1,600
OncoCyte Common Stock Option Plans [Member]
Shares Available for Grant [Roll Forward]
Beginning of the period (in shares)	1,757,000	1,278,000	1,250,000
Increase in option pool (in shares)		4,000,000
Options granted (in shares)	(962,000)	(2,875,000)	(1,590,000)
Options exercised (in shares)	0	0
Options expired/forfeited/cancelled (in shares)	35,000	1,121,000	28,000
2 for 1 reverse stock split (in shares)		(1,762,000)
Options granted after reverse stock split (in shares)		(10,000)
Options forfeited/cancelled after reverse stock split (in shares)		5,000
Restricted stock issued (in shares)			(400,000)
Options expired (in shares)	50,000
End of the period (in shares)	880,000	1,757,000	1,278,000
Number of Options Outstanding [Roll Forward]
Outstanding, beginning of the period (in shares)	2,240,000	2,722,000	2,750,000
Increase in option pool (in shares)		0
Options granted (in shares)	962,000	2,875,000	1,590,000
Options exercised (in shares)	(100,000)	(6,000)	(3,000)
Options forfeited/cancelled/expired (in shares)	(35,000)	(1,121,000)	(28,000)
2 for 1 reverse stock split (in shares)		(2,235,000)
Options granted after reverse stock split (in shares)		10,000
Options forfeited/cancelled after reverse stock split (in shares)		(5,000)
Options expired (in shares)	(50,000)
Restricted stock issued (in shares)			200,000
Outstanding, end of the period (in shares)	3,017,000	2,240,000	2,722,000
Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of the period (in dollars per share)	$ 2.94	$ 0.76	$ 0.76
Increase in option pool (in dollars per share)		0
Options granted (in dollars per share)	3.58	1.10	2.50
Options exercised (in dollars per share)	2.19	0.67	2.34
Options forfeited/cancelled (in dollars per share)	2.03	0.79	1.00
2 for 1 reverse stock split (in dollars per shares)		2.02
Options granted after reverse stock split (in dollars per share)		3.60
Options forfeited/cancelled after reverse stock split (in dollars per share)		2.00	2.34
Options expired (in dollars per share)	2.00
Outstanding end of the period (in dollars per share)	$ 2.52	$ 2.94	$ 0.76
Shares Available for Grant [Roll Forward]
Increase option pool (in shares)		4,000,000
Granted (in shares)	(962,000)	(2,875,000)	(1,590,000)
Restricted stock issued (in shares)			(400,000)
Exercised (in shares)	0	0
Forfeited/cancelled/expired (in shares)	35,000	1,121,000	28,000
Number of Options Outstanding [Roll Forward]
Increase option pool (in shares)		0
Granted (in shares)	962,000	2,875,000	1,590,000
Exercised (in shares)	(100,000)	(6,000)	(3,000)
Forfeited/cancelled/expired (in shares)	(35,000)	(1,121,000)	(28,000)
Number of RSUs Outstanding [Roll Forward]
RSUs (in shares)			200,000
Weighted Average Exercise Price [Roll Forward]
Increase option pool (in dollars per share)		$ 0
Granted (in dollars per share)	$ 3.58	1.10	$ 2.50
Exercised (in dollars per share)	2.19	0.67	2.34
Forfeited/cancelled/expired (in dollars per share)	$ 2.03	$ 0.79	$ 1.00
Additional Information regarding options outstanding [Abstract]
Authorize number of shares under stock option plan (in shares)	4,000,000
Cell Cure Neurosciences' Option Plan [Member]
Additional Information regarding options outstanding [Abstract]
Authorize number of shares under stock option plan (in shares)	125,363
Lifemap Stock Option Plan [Member]
Additional Information regarding options outstanding [Abstract]
Authorize number of shares under stock option plan (in shares)	8,000,000
LifeMap Solutions, Inc [Member]
Additional Information regarding options outstanding [Abstract]
Authorize number of shares under stock option plan (in shares)	18,667

Stock Option Plans, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
All stock-based compensation expense [Abstract]
Total stock-based compensation expense	$ 7,951	$ 11,050	$ 4,455
Research and Development [Member]
All stock-based compensation expense [Abstract]
Total stock-based compensation expense	2,608	3,267	1,310
General and Administrative [Member]
All stock-based compensation expense [Abstract]
Total stock-based compensation expense	$ 5,343	$ 7,783	$ 3,145

Stock Option Plans, Subsidiaries' Stock Options Plans (Details) - $ / shares
shares in Thousands

12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

OrthoCyte Corporation [Member]

1,371

1,355

^[1]

1,329

2,700

1,371

1,355

^[1]

2,629

2,645

^[1]

(1,329)

(16)

1,300

2,629

2,645

^[1]

Outstanding, beginning of the period (in dollars per share)

$ 0.08

^[1]

Outstanding end of the period (in dollars per share)

0.10

0.07

$ 0.06

$ 0.08

^[1]

ReCyte Therapeutics, Inc. [Member]

2,721

2,710

^[1]

2,750

2,721

2,710

^[1]

1,279

1,290

^[1]

(29)

(11)

1,250

1,279

1,290

^[1]

Outstanding, beginning of the period (in dollars per share)

$ 2.05

^[1]

Outstanding end of the period (in dollars per share)

2.05

$ 2.05

^[1]

LifeMap Sciences, Inc. [Member]

547

471

413

(20)

(131)

219

207

746

547

471

1,795

1,871

1,929

131

(219)

(207)

(58)

1,596

1,795

1,871

Outstanding, beginning of the period (in dollars per share)

$ 1.47

$ 1.48

$ 1.49

Granted (in dollars per share)

2.25

1.92

Outstanding end of the period (in dollars per share)

1.72

1.79

1.48

$ 1.44

$ 1.47

$ 1.48

LifeMap Solutions, Inc [Member]

Option pool added upon incorporation (in shares)

(2)

(13)

(4)

(1)

Outstanding, beginning of the period (in dollars per share)

$ 500.00

Granted (in dollars per share)

500.00

$ 500.00

Outstanding end of the period (in dollars per share)

500.00

$ 500.00

BioTime Asia, Limited [Member]

Stock option available for future grants (in shares)

1,300

300

Outstanding end of the period (in dollars per share)

$ 0.01

Cell Cure Neurosciences, Ltd. [Member]

^[2]

(69)

Increase to option under 2016 share option plan (in shares)

^[2]

111

^[2]

Increase to option under 2016 Share Option Plan (in shares)

^[2]

Outstanding, beginning of the period (in dollars per share)

^[2],[3]

$ 23.93

Granted (in dollars per share)

^[3]

40.00

Increase to option under 2016 share option plan (in dollars per share)

^[3]

Outstanding end of the period (in dollars per share)

^[3]

$ 38.00

$ 23.93

^[2]

[1]	There was no grant activity during 2014.
[2]	There was no grant activity during 2014 and 2015.
[3]	Cell Cure Neurosciences Share Option Plan US dollar exercise price shown is approximated based on the conversion rate between the US dollar and the New Israeli Shekel, NIS, at the time of grant. The exercise price is denominated in NIS.

Commitments and Contingencies (Details)

12 Months Ended

Dec. 31, 2016

USD ($)

ft²

m²

Building

Option

Dec. 31, 2015

USD ($)

Dec. 31, 2014

USD ($)

Dec. 31, 2016

ILS (₪)

ft²

m²

Alameda Operating Lease Future Payments Due Fiscal Year Maturity [Abstract]

$ 797,000

822,000

844,000

870,000

896,000

1,002,000

5,231,000

Minimum annual lease payments under the various operating leases [Abstract]

2017

1,098,000

^[1]

2018

1,045,000

^[1]

2019

1,042,000

^[1]

2020

1,048,000

^[1]

2021

897,000

^[1]

Thereafter

1,002,000

^[1]

Total

6,132,000

^[1]

Minimum annual lease payments under capital leases [Abstract]

202,000

217,000

93,000

$ 512,000

New Alameda Lease [Member]

Operating Leased Assets [Line Items]

Lease term

7 years

Number of years lease can be extended

5 years

Leased area | ft²

30,795

Number of buildings for lease | Building

Base rent

$ 64,670

Base rent increase rate

3.00%

Tenant improvement allowance

$ 1,400,000

Security Deposit

847,000

Security deposit reduction in value after first twenty four months of lease term

423,000

Security deposit reduction in value after first thirty six months of lease term

346,000

Reporting Entities [Member] | Office space in New York City [Member]

Operating Leased Assets [Line Items]

Base rent

$ 5,050

Cell Cure [Member] | Office and laboratory space, Jerusalem, Israel [Member]

Operating Leased Assets [Line Items]

Number of years lease can be extended

5 years

Leased area | m²

1,128

Base rent

$ 14,400

₪ 55,218

Rent expenses

$ 1,500,000

$ 2,100,000

$ 2,000,000

Number of five year options to extend lease term | Option

Research and Development Licensing Agreements [Member]

Royalty Obligations and License Fees [Abstract]

License fees and related expenses

$ 180,000

$ 282,000

$ 432,000

Research and Development Licensing Agreements [Member] | Minimum [Member]

Royalty Obligations and License Fees [Abstract]

Minimum annual maintenance fees

140,000

Research and Development Licensing Agreements [Member] | Maximum [Member]

Royalty Obligations and License Fees [Abstract]

Minimum annual maintenance fees

$ 160,000

[1]	Includes the lease of our principal office and laboratory facilities in Alameda, California, including the lease liability, leases of the offices and laboratory facilities of LifeMap Sciences, Cell Cure and other operating leases of lab equipment.

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets/(liabilities) [Abstract]
Net operating loss carryforwards	$ 78,116,000	$ 78,268,000
Research and development and other credits	7,645,000	8,331,000
Patents and licenses	(67,000)	(6,860,000)
Equity method investments	(40,258,000)	(1,333,000)
Stock options	1,529,000	670,000
Other, net	2,248,000
Other, net		(263,000)
Total	49,213,000	78,813,000
Valuation allowance	(49,213,000)	(78,813,000)
Net deferred tax liabilities	$ 0	$ 0
Income tax rate reconciliation [Abstract]
Computed tax benefit at federal statutory rate	34.00%	34.00%	34.00%
Research and development and other credits	(3.00%)	2.00%	3.00%
Permanent differences	2.00%	(4.00%)	(1.00%)
Change in valuation allowance	(63.00%)	(34.00%)	(24.00%)
State tax benefit, net of effect on federal income taxes	24.00%	10.00%	3.00%
Foreign rate differential	6.00%	(1.00%)	(1.00%)
Total	0.00%	7.00%	14.00%
Tax Credit Carryforward [Line Items]
Net operating loss carryforwards for federal tax purposes	$ 171,100,000
Net operating loss carryforwards for state tax purposes	$ 95,000,000
Period in which change of ownership for a specified percentage should occur	3 years
Gain on deconsolidation of Asterias	$ 49,048,000	$ 0	$ 0
Unrealized gain	34,361,000	0	0
Taxable gain on asset transfer	3,100,000
Deferred income tax benefit	0	(4,516,000)	(7,376,000)
Deferred federal income tax benefit		(4,800,000)	(5,200,000)
Deferred state income tax benefit		290,000	$ (2,200,000)
Accrued interest and penalties	0
Asterias Biotherapeutics [Member]
Tax Credit Carryforward [Line Items]
Gain on deconsolidation of Asterias	49,000,000
Taxable gain on sale of subsidiary shares		$ 819,000
OncoCyte Corporation [Member]
Tax Credit Carryforward [Line Items]
Net operating loss carryforwards for federal tax purposes	30,600,000
Net operating loss carryforwards for state tax purposes	15,100,000
Number of shares sold by subsidiary (in shares)		259,712
Taxable gain on sale of subsidiary shares		$ 815,000
Shares distributed to shareholders (in shares)		4,700,000
Taxable gain on shares distribution		$ 7,400,000
LifeMap Sciences [Member]
Tax Credit Carryforward [Line Items]
Net operating loss carryforwards for federal tax purposes	22,700,000
BioTime Subsidiaries [Member]
Tax Credit Carryforward [Line Items]
Foreign net operating loss carryforwards	58,500,000
Amount utilized in net operating loss carryforwards		$ 9,100,000
Federal [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	3,800,000
State [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	$ 3,900,000

Enterprise-wide Disclosures (Details) - USD ($)
$ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Revenues from External Customers and Long-Lived Assets [Line Items]

Total revenues

$ 1,103

$ 1,441

$ 1,171

$ 1,848

$ 1,306

$ 1,874

$ 1,749

$ 1,000

$ 5,923

$ 7,036

$ 5,244

Long-lived assets

5,529

^[1]

7,539

5,529

^[1]

7,539

Domestic [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

Total revenues

4,497

5,976

3,586

Long-lived assets

3,418

^[1]

7,132

3,418

^[1]

7,132

Foreign [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

Long-lived assets

$ 2,111

^[1]

$ 407

2,111

^[1]

407

Asia [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

Total revenues

$ 1,426

$ 1,060

$ 1,658

CIRM Grant Income [Member]

N I H Grant Income [Member]

38.00%

42.70%

19.70%

IIA (formerly OCS) grant income (Cell Cure, Israel) [Member]

0.00%

6.50%

12.50%

Subscription, Advertising and Other (various customers) [Member]

24.00%

14.40%

31.30%

^[2]

35.00%

29.40%

32.50%

Other [Member]

LifeMap Sciences, Ltd. [Member]

^[2]

3.00%

7.00%

4.00%